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ABSTRACT OF DISSERTATION

A NOVEL NONPARAMETRIC TEST FOR HETEROGENEITY DETECTION
AND ASSESSMENT OF FLUID REMOVAL AMONG CRRT PATIENTS IN ICU
Over the past decade acute kidney injury (AKI) has been occurring among 20%-50%
of patients admitted to the intensive care unit (ICU) in United States. Continuous
renal replacement therapy (CRRT) has become a popular treatment method among
these critically ill patients. But there are multiple complications in implementing this
treatment, including discrepancies in practiced and prescribed fluid removal, possibly
related to the heterogeneity among these patients. With mixture modeling there have
been several techniques in detecting heterogeneity with their specific limitations. In
this dissertation a novel nonparametric ‘d test’ will be used to detect heterogeneity
among CRRT patients in ICU. Along with heterogeneity detection, this dissertation
will also seek to understand ongoing issues with fluid removal and discrepancy in
treatment implementations.
KEYWORDS: CRRT, Heterogeneity, Discrepancy, Biostatistics, Systematic-Review.
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Chapter 1 Introduction

1.1

Mixture Model

A Mixture model is a probabilistic model that represents the distributions of the subpopulations in an overall population [1]. A distribution f is a mixture of K component
distributions f1 , f2 , ..., fK if,

f (x) =

K
X

pi fi (x)

i=1

where, pi are the mixing weights with 0 ≤ pi ≤ 1 and

Pk

i=1

pi = 1. A finite Gaussian

or normal mixture model is where the ith components are N (µi , σi ). That is,

f (x) =

K
X

pi N (x|µi , σi )

(1.1)

i=1

1.1.1

Application and Example

Mixture models are famous for heterogeneity detection. Normal mixture models have
been used in gene filtration in microarray analysis, neuroimaging pattern recognition,
disease mapping and numerous other issues in public health [2–7].
For example, birthweight is one of the prognostic factors for fetal-infant mortality.
With low and extremely low weights at birth, the mortality risk increases and thus
need special attention to these groups. Charnigo et. al. [8] applied a normal mixture
model to birthweight and fetal-infant mortality data to build a realistic and flexible
framework for birthweight age distribution. The number of components in the mixture model is determined from data using Flexible Information Criterion(FLIC) [9].
The authors used the EM algorithm [10] to apply FLIC by using maximum likelihood

1

estimate of proportions, mean and standard deviation. They also investigated the
relationship between sample size and the number of components selection, where 4
components were chosen for their 50,000 random samples from 202,849 of white singletons. With the comparison of the 4 components model to the contaminated normal
model and 2-components model, the 4 components model averted the weaknesses of
the other two models [8]. The authors also compared how each component fits the
tails of the distributions to the clinical groups of birthweight distribution. That is,
they checked how the components model fits the MLBW (medium-low birthweight)
range. By comparing the criteria preferences, the authors concluded that, a multiple
components (> 2) normal mixture model detects the heterogeneity and reasonably
describes the birthweight distribution when compared to a contaminated normal or
a 2-components normal mixture model.

1.2

Implementation of Mixture Model

Numerous methods for estimating the parameters of a mixture model (pi , θi ), where
θϵΘ(parameter space), have been proposed. Some suffer from theoretical complications, some suffer from computational challenges. Moreover, the log-likelihood function of a mixture distribution does not have a closed form solution and regarded as
incomplete without prior knowledge [10, 11]. Below are some of the popular methods
used in implementing the mixture model.

1.2.1

EM algorithm

The EM (Expectation-Maximization) algorithm is a popular approach for finding
maximum likelihood estimates with missing or incomplete data. The EM algorithm
approaches to find the value of the parameter using sampling density depending on
the parameter and the data, which maximizes the sampling density given the observed
response. With the popularity of the maximum likelihood method [12], Dempster et

2

al. (1977) [10] explored the EM algorithm’s properties in detail. They showed that,
along with the maximum likelihood framework, the EM algorithm can be applied in
a Bayesian setting. They also investigated different approaches of the EM algorithm
in different scenarios (different types of exponential families and non-exponential
families), which can be simplified as followsE-step (Expectation): After choosing appropriate initial values, find the appropriate
expected value (e.g., likelihood, quasi-likelihood, etc.) given the current estimate of
the parameter.
M-step (Maximization): Find the parameter estimate that maximizes the abovementioned expected value.
Convergence (with the increase of iterations) to maximum likelihood is ensured with
the assumption of continuity and differentiability conditions. Also, differentiation
and expectation operations are assumed to be interchangeable.
Redner & Walker (1984) [12] investigated the theoretical and iterative properties of
the EM algorithm for mixture densities. They used exponential families as the point
of interest due to the majority of literature involving mixture densities, including
component densities, being members of exponential families. The performance of
the EM algorithm was satisfactory as the authors mentioned that process has “good
global convergence characteristics” (p-231).
Although the EM algorithm is thought to obtain global maxima with carefully chosen
initial values, this might not be the case always. Some initial values might lead the
EM algorithm to get stuck at local maxima. Thus, careful consideration should be
given in choosing initial values. The EM algorithm can be used initially, and later,
Newton-Raphson’s iterative approach can be used for rapid local convergence. [12]

3

1.2.2

Likelihood Ratio Test

G. J. McLachlan (1987) [13] proposed using LRT (Likelihood Ratio Test) to find the
smallest number of components in a normal mixture model when there is no prior
knowledge. He used bootstrapping of the log-likelihood ratio statistic and performed
simulations to test the simplest situation- one component vs two components. Because there is no way to be sure that the largest of the local maxima will be found
in the log-likelihood for mixtures, the likelihood ratio statistic (−2loglambda) may
be biased downard, where λ is the likelihood ratio under the null and alternative
hypotheses. The EM algorithm [10] was used to limit this bias through a systematic
search for all local maxima using multiple sets of initial values. Also, to avoid the situation of having two local maxima because of the components belonging to the same
parametric family, it was conditioned that the mean of the first component should
be less than the mean of the second component. The simulation results showed that,
if the distances between the components were larger then the test would be more
powerful. The author also tested 2 components vs 3 components with the condition
of a consecutive increase in the means of the components and found similar results
supported by bootstrap simulations.
Hanfeng Chen and Jiahua Chen (2001) [11] studied the large sample behavior of
LRT for testing homogeneity under a two-components mixture model. To have a
limiting distribution for LRT, the parameter space needs to be bounded, otherwise,
the LRT goes to infinity with probability 1 [14]. After describing the regularity
conditions, the authors stated that the asymptotic null distribution of the LRT for
the two-component mixture model is the squared supremum of a truncated gaussian
process. They mentioned that this asymptotic distribution is complex because the
null asymptotic distribution depends on how large the parameter space is, thus the
bounded condition was implied. They also did bootstrap simulation [McLachlan, G.
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1987] for testing homogeneity with different kernel functions (Normal, Binomial, and
Poisson). The result concluded that at a 5% level of significance, the approximation
improves with the increase of sample size, and the simulation study agreed with the
consistent performance of LRT.
Since the likelihood ratio test (LRT) for homogeneity in finite mixture models has
complicated asymptotic properties [11] Chen et al. [15] proposed a modified likelihood
ratio test (MLRT) with similar power and easier asymptotic properties. They showed
that the asymptotic null distribution is a weighted mixture of central χ21 and χ20 distribution. χ20 is the degenerate distribution with all of it’s values are at 0. The MLRT
has a penalty term that affects the maximized likelihood only under the alternative
hypothesis. The estimated weights of the mixture components in the heterogeneous
model are forced to be away from 0 by the penalty term, which helps estimate the
parameters of the different components.

1.2.3

D Test

Richard Charnigo and Jiayang Sun (2004) [16] presented a new method, the D test,
for testing the homogeneity of the finite mixture distribution. The D-test statistic has
a closed-form expression for mixture components from standard parametric families
in terms of parameter estimators, whereas likelihood ratio type test statistics do
not. The D test employs an “L2 ” distance between a fitted homogeneous model and
a fitted heterogeneous model, based on Scott’s (1998) [17] L2 E method for model
selection. The reason for choosing L2 distance is that it puts more emphasis on
the larger separations between the homogeneous and heterogeneous density curves
and also leads to a simple closed-form expression so that the test is sensitive to the
separation between the null and the specific alternative under consideration.

5

The D test statistic is defined as,
Z
d(k, n) :=

k
X

2
p̂i f (x|θˆi ) − f (x|θˆ0 ) dx

(1.2)

i=1

where k is the number of distinct components under the alternative hypothesis and
n is the sample size. The authors found that the D-test has more power to detect
homogeneity compared to the MLRT in simulation study when the mixture components come from a normal location family, but the generalization of MLRT to a
two-parameter family tends to perform better than D test when mixture components
come from a normal location/scale family. Because L2 distance increases the smallest
distance between shapes, it is easy to detect subtle changes when there is heterogeneity. Moreover, with a small sample size, it becomes difficult to detect heterogeneity in
exponential mixture densities. To overcome this weakness, the authors also proposed
a weighted D test [16] where the L2 distance is changed to accentuate the disparities.
They also found another equivalent way by changing the measure or transforming
the data before conducting the D test. To check the D test’s feasibility, the authors
applied it to the bankruptcy data from Johnson and Wichern (2002) [18] and found
satisfactory results.
Later, the authors [19] investigated the asymptotic equivalences between the Dtest and three other likelihood ratio type tests (LR test, MLRT [Chen, Chen and
Kalbfleisch 2001] [15] and EM test [Li, Chen and Marriott 2009] [20] ). With the
same mixture from a regular exponential family using Chen, Chen and Kalbfleich’s
(2001) [15] penalized likelihood bayesian framework, the authors showed an asymptotic critical value related to the upper 2α quantile of the chi-square distribution on
one degree of freedom. Thus, under contiguous local alternatives, the power should
stabilize to some larger amount close to 100% and this simple limiting null distribution
makes the D test asymptotically locally most powerful. To investigate finite-sample
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accuracy of critical values, the authors used MLRT as a benchmark for simulation
studies on the mixture from the one-dimensional exponential family and the EM test
as a benchmark for normal location mixtures with unknown structural parameters,
i.e. variance in this case. Compared to LRT and MLRT, which need both full dataset
and parameter estimates, the D test depends on the data only through the applicable
framework of parameter estimation.

1.3
1.3.1

D-Test in Application
Real Data Heterogeneity Detection

Charnigo and Sun [19] applied the empirical Bayesian framework D-test to the SLC
dataset (Roeder 1994) [21] and found that both EM test and empirical Bayesian
framework D test suggest heterogeneity in the form of what the authors called “a highlow probability mixture”, where the first component gets much higher probability and
second components get much lower probability.

1.3.2

Contamination Detection

In a mixture model when one component’s parameters are known, then it is defined
as a contaminated density model [22]. In a regression model to test for contamination
to describe a subpopulation, Dai and Charnigo explored the asymptotic and finite
sample performance of the MLRT (Modified Likelihood Ratio Test) and the D test.
The authors are interested in testing zero contamination vs. non-zero contamination
and have developed easily applicable inferential methods for contaminated density and
regression models. For the contaminated density model, the authors considered using
a weighted D-test, and for the contaminated regression model, when the probability
density function for the explanatory variable is unknown, the authors considered using
an empirical D test. Their empirical assessment showed that the tests distinguish
contamination easily when the contamination fraction is large, even if the component
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means are not separated enough. Power can be retained with a small contamination
fraction if the sample size is large or the component means differ greatly. For the
contaminated density model, the authors concluded that using an appropriate weight
function improves the power to detect contamination. The authors pointed out that
MLRT and D tests can be used to check whether apparent outliers are a part of
subpopulation, which is a paramount aspect of the data analysis.

1.3.3

Gene Filtration:

To detect gene expression alterations, Dai and Charnigo (2008) [2] used the Modified
Likelihood Ratio Test (MLRT) and the D test to adjust for the large number of
simultaneous tests corresponding to the number of genes. Because, when we try to
control the false positive rate in large scale multiple testing, the false-negative rates
become extremely large. Thus, in large-scale testing, traditional methods have low
power to detect differential gene expression, failing to compare groups efficiently.
From previous work of Allison et al.(2002) [23], in large scale hypothesis testing, Pvalues for genes without expression alterations are distributed as iid U(0,1)= β(1, 1)
and differentially expressed genes’ P-values are assumed to be distributed as a Beta
distribution with different parameter values. Thus, Dai and Charnigo proposed a
beta contamination model to define the marginal distribution of the P-values obtained
from large scale gene studies. Because of the abundance of less important genes in
such studies, the authors suggested omnibus homogeneity testing as part of a gene
filtration process which separates the genes by their differential expression rates using
the following hypotheses:
H0 : Pi ∼iid Beta(α0 , β0 )
H1 : Pi ∼iid (1 − π)Beta(α0 , β0 ) + πBeta(α, β) ̸= Beta(α0 , β0 )
where α0 and β0 are known and π ∈ [0, 1], α > 0, β > 0.
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To test for goodness of fit for the null model, i.e. Beta(1,1) model MLRT and D
test were used. A maximum modified likelihood estimate (MMLE) was used to test
the hypothesis of whether a uniform model was appropriate or not. To test the
performance of the D test and MLRT, two empirical studies were conducted where
one was concerned with the actual rejection rates under the null hypothesis that the
distribution is from a beta(1, 1) model and the other was concentrated on the power
under the alternative hypothesis when critical points from asymptotic theory were
used. The simulation study confirmed that the D test and MLRT have advantages in
both scenarios. The authors assumed independence of P-values and concluded that
contaminating beta distribution helps to detect substantial differential expressions
under certain assumptions of the parameters.
The contaminated beta (CB) model is useful for describing the distribution of Pvalues resulting from a microarray experiment. Dai and Charnigo (2010) proposed
using the contaminated normal (CN) model instead of the CB model to describe the
distribution using Z-statistics instead of P-values. Balancing type I and type II error
rates with a large number of hypothesis tests is challenging. The authors suggested
that if unnecessary genes can be filtered out through omnibus testing, with fewer
genes under consideration, greater power can be achieved in hypothesis testing while
maintaining the type I error rate. Thus, they investigated the asymptotic behavior
of MLRT (Modified Likelihood Ratio Test) and D test for omnibus testing using the
following hypothesis tests:
H0 : γµ = 0
vsH1 : γµ ̸= 0
where γ is the proportion of genes that are differentially expressed and µ is the mean
Z-statistic of genes that are differentially expressed. Maximum modified likelihood
reduces the non-identifiability problem by pushing γ away from 0 using a penalty term
9

(Chen, Chen and Kalbfleisch 2001) [15]. Dai & Charnigo also used KolmogorovSmirnov for simulation study to compare CN and CB [24]. The simulation result
showed CN to be more powerful in detecting differential expression than the CB
model for some specific cases: when either overexpression or underexpression of genes
is more prevalent than the other (that is, asymmetric), when the ratio of |µ| and σ
is moderate, and when two-sided tests are preferred to one-sided tests. That is when
there is no assumption on the sign of µ given that µ > 0 corresponds to overexpression
and µ < 0 corresponds to underexpression, CN is preferable. But if there is prior
knowledge about the direction of µ then a right-sided test for detecting overexpression
and a left-sided test for detecting underexpression is preferred. In these cases, CB is
superior to CN. CN and CB can also be used to estimate the fraction of differentially
expressed genes.
To understand real-life applicability, the authors used real microarray data of 10
SARS patients and 4 healthy controls from a study on expression levels of immune
response genes [25]. The data is also available at the Gene Expression Omnibus of
the National Center for Biotechnology Information. Charnigo and Dai compared the
performances of CN and CB. They found that γ̂ is much larger in CB than in CN
because, unlike CN, CB does not assume differential expression to lie in mainly one
direction. They compared the performances of CB and CN by computing maximized
modified log-likelihoods and concluded that the CB model performs better for this
data set. One advantage in comparing CB and CN is that these two models have
the same number of parameters and thus, can be compared based on a BIC-type
criterion. The authors pondered the limitations of CN in the case of a symmetrical
distribution of Z-statistics and concluded that it can be overcome by using extended
two contaminated components in the CN model.
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1.4

Nonparametric Approach in Mixture Model

Nonparametric methods are becoming quite popular now in identifying clusters. With
all the parametric, semi-parametric approaches discussed in the previous sections, we
explored some ideas in the field of nonparametric clustering and classification techniques (where one is an unsupervised learning method and the other is a supervised
learning method) for detecting heterogeneity without applying mixture modeling. We
will discuss both
Hastie et. al. described a kernel or weight function technique that provides flexibility in estimating a regression function with multiple inputs in chapter 6 “Kernel
Smoothing Method” [26]. The technique fits different simple models at each target
point separately, along with assigning weights to chosen points based on their distance from the corresponding target points. This method is dependent on training
data only and requires only determining the neighborhood distance indexed by λ.
For example, Epanechnikov quadratic kernel is given as follows:

Kλ (x0 , x) = d(

|x − x0 |
)
λ

with d(t) = 34 (1 − t2 ) if |t| < 1 else, 0 otherwise.
For one-dimensional kernel smoothers, the authors suggested local linear regression
and local polynomial regression. Local linear regression is a nonparametric approach
in which the f(x) in a regular fitted regression model (y = f(x) + ϵ) is nonlinear but
behaves linearly when divided into small regions. For local linear regression, locally
weighted averaging has a bias problem at or near the boundaries of the domain, but
with less variance. On the other hand, local polynomial regression reduces bias at
boundaries but has increased variance. Also, there is a bias-variance trade-off with
the change of the width of the averaging window. This is very important as the
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choice of width, either as fixed or variable, has a big impact on kernel smoothing.
The authors suggested that if extrapolation is of interest then, local linear fits are
probably more trustworthy than local polynomial fits of higher order.
This local regression technique comes with its own characteristic limitations. When
the dimension is more than 2 or 3, the difficulty in visualization and the choice
of kernel make local regression less useful. The authors suggested that when the
dimension to sample size ratio is very large, structural assumptions about the kernel or
the regression function make local regression helpful. For structured kernel, when we
have multiple inputs, we have the option of choosing multiple bandwidths (we could
also choose one tuning parameter instead of two, in this case we could standardize
each input variable to unit standard deviation). For structured regression function,
we can use one-dimensional local regression to estimate analysis of variance (ANOVA)
decompositions.
With the broad concept of local regression, the authors suggest that if a parametric
model is fitted by accommodating observation weights, then it will be called local.
The local likelihood estimation technique is a smoothing technique based on local
polynomials in non-gaussian regression models. This is useful because, the local
likelihood does not restrict the data analyst to a parametric model, which is a globally
linear or generalized linear model, which may be unreasonable versus a locally linear
or generalized linear model. The authors also suggested avoiding the dimensionality
problem by assuming an additive structure of the regression function, as generalized
additive models using kernel smoothing methods are closely related to multiclass
linear logistic regression models.
The authors also talked about kernel density estimation, which is an unsupervised
learning procedure with an application for nonparametric classification. They discussed how a discontinuous histogram estimate can be smoothed by using the Parzen
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estimate from Loader (1999) [27]. They suggested using nonparametric estimated
densities for classification, using Bayes’ theorem. Also, when classification is the ultimate goal, we only need to estimate close to the decision boundary. They have
discussed a naı̈ve Bayes classifier where a naı̈ve Bayes model assumes features are
independent given a class. It becomes easy to estimate class-conditional marginal
densities. Even though the estimated marginal class densities are biased, it doesn’t
affect the posterior probabilities near the decision boundaries. When we are not sure
about integrating the estimated density function to 1, the radial basis function uses a
kernel type argument for localization. A basis function by itself is not flexible enough
to show local behavior. That is, we can use the basis function without positivity
constraints.
The authors discussed how all this information can be used to create a mixture model
for density estimation and classification. Even though the Gaussian mixture model
is very popular, the authors popularized the concept of the mixture model: “mixture models can use any component densities in place of the Gaussian” (page-214).
They also mentioned two special cases when the covariance matrices are restricted
to a scalar multiple of the diagonal than the gaussian mixture model is related to
a radial basis function. Also, when component variances are equal and the number
of components increases with the sample size, the maximum likelihood estimates for
the Gaussian mixture model approach Kernel density estimate.

1.5

Future Direction with Heterogeneity Detection

In this chapter, we have explored the wide applicability of mixture modeling and
its limitations in implementations and nonparametric approaches. Keeping in mind
the limitations of both parametric and nonparametric approaches, we aim to find a
feasible test for heterogeneity detection that improves the limitations of parametric
tests.
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As discussed in the previous section, when the number of mixture components is
large with a large sample size, the maximum likelihood estimates approach the kernel
density estimate. This encouraged us to use kernel density as a alternative fit for
detecting heterogeneity. Thus, we would explore how a nonparamteric density estimate can be used to obtain a heterogeneity detection test without worrying about
the actual number of components that exist.

1.6

Acute Kidney Injury and Continuous Renal Replacement Therapy

Over the past decade, one of the most frequent complications among patients who are
admitted to the intensive care unit (ICU) acute kidney disease (AKI) [28–30]. With
injured kidney the human body cannot filter out enough waste and toxic substances
and as a result, the body starts to accumulate excessive fluids [31]. Continuous renal
replacement therapy (CRRT) has become popular among critically ill patients as an
efficient treatment for removing excess fluid from the body [32, 33].
Since the health condition among ICU patients are not always stable, the application
of CRRT is always challenging, from finding an optimal fluid removal rate to implementing the treatment [34–36]. With several complications in the ICU, it may be
beneficial for clinicians to identify clusters of patients to provide specific treatments
and obtain optimal results. Also, identifying other problems and consequences, will
be beneficial to finding better healthcare solutions.
1.6.1

Fluid overload

Fluid overload (FO) is the medical term for the condition when the blood contains
a higher liquid portion (plasma) [37, 38]. A healthy body contains a certain amount
of fluid based on age and weight, because their kidney removes excess fluid from
the body. But with a dysfunctional kidney body can not remove excess fluid and
causes FO. It can also be caused by heart or liver failure, hormonal imbalance, or
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excessive intravenous (IV) fluid transfer [38]. The majority of the cases are associated
with kidney disease [39]. Most of the AKI patients in the ICU suffer from end stage
kidney failure or injured kidney. Thus, FO is a common problem among people with
acute [40, 41] or chronic kidney disease [42].
To quantify FO, Goldstein et. al. [43] proposed the following formula adjusted for
the body weight,

FO = (fluid intake − fluid output)/admission weight × 100%

1.6.2

NUF rate and Mortality

The net ultrafiltration (NUF) is used to measure the amount of fluid needed to be
removed to attain fluid balance (FB). It is defined as the volume of fluid removed per
hour adjusted for patients body weight. NUF rate or intensity is measured [44] as
follows:

NUF rate (ml/kg/h) =

Total NUF volume (ml)
weight(kg) × treatment duration (h)

In general NUF has been categorized in three groups.
• Low: <1.01 ml/kg/h
• Moderate: 1.01 to 1.75 mL/kg/h
• High: >1.75 ml/kg/h
It has been more than 70 years since NUF has been used in controlling FO [45], but
the optimum rate has still not been determined. Some studies [46, 47] suggested that
less intensive (slower rate or smaller volume) NUF may be associated with tissue
and organ swelling and increased morbidity and mortality, whereas some studies
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suggested [48,49] faster rate or larger volume causes hemodynamic and cardiovascular
stress, which also leads to increased morbidity and mortality.
Given the inability of patients to tolerate therapy and contradicting findings in multiple articles on the association between greater NUF rates and mortality, it appears
that there may be a discrepancy in recommended and implemented NUF rates. Murugan, Ostermann et. al. conducted a multinational internet-assisted survey in 80
countries to understand the attitudes and practices of practitioners with respect to
NUF prescription [50].
They have pointed out major issues that are causing the discrepancy summarized
below.
• Patient intolerance (hypotension, diabetes, health condition etc.)
• Frequent interruption (visit for lab tests, machine malfunction etc.)
• Undertrained Nursing staff.
• Unavailability of the machines and cost associated with treatment.
There are various challenges in assessing human error in the implementation of CRRT.
However, we may investigate if the treatment’s execution is also influenced by other,
controllable phenomena. It’s probable that the patient’s intolerance is the greatest obstacle to achieving the prescribed fluid removal. Identification of some other
modifiable factors that play even a small role in creating a discrepancy in treatment
implementation, is also crucial in improving patient healthcare. We propose to identify groups of patients by applying heterogeneity detection techniques and how they
can be utilized to understand the treatment discrepancy.
More investigation is required to understand the disparities in previous literature
findings. We proposed a systematic literature review to explore the key findings and
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identify reasons for variation in results. We will also explore fluid removal issues
among CRRT patients to identify key patient characteristics that lead to increased
mortality risk, as well as how the CRRT discrepancy relates to other ICU parameters.

Copyright© Shaowli Kabir, 2022.
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Chapter 2 Nonparametric D test

2.1

Introduction

Mixture modeling is a scientific tool for clustering observed data based on some
unobserved characteristics. From public health to astronomy, finite mixture models
have been widely used to detect heterogeneity [51–53]. Image segmentation [54],
disease mapping [55], genetics trait mapping [56, 57] and so many other fields of
study have been applying mixture modeling. With the versatile applicability, mixture
models are also used in large scale hypothesis testing to adjust for increased numbers
of false positives. In large scale hypothesis testing each test results becomes a data
point for mixture modeling to cluster: those of scientific interest vs those not [58].
When increased number of false positives makes the multiplicity adjustments difficult
to apply, mixture models can discard numerous results through a so called omnibus
test [2].
Likelihood ratio test (LRT) [11] [59] has been initially proposed to test for homogeneity in mixture models. Considering complicated asymptotic properties and critical
value bootstrap issues, several other methods have been proposed for heterogeneity
detection [13,15]. For example, Charnigo and Sun used a L2 distance based technique
called d-test in mixture distribution [16]. They compared the null hypothesis to an
alternative hypothesis with specified number of components. But this comes with the
challenge of being confident on the number of components that need to be tested.
With the uncertainty of the number of components in alternative hypothesis, multiple
testing and adjusting for type I error in sequential testing becomes difficult and time
consuming. Also, d test as originally proposed may not have the flexibility to detect
variety of departures from homogeneity. Thus we propose a nonparametric version
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of the d test which accounts for the various possible departures from homogeneity
based on Kernel smoothing and empirical null hypothesis [58]. In particular our test
is intended to capture departures from homogeneity that can occur with model misspecification. That is, our robust test will help to reject the incorrect null hypothesis
and detect heterogeneity not only without specifying the number of components but
also without requiring a finite number of components from same parametric family.
The nonparametric d test (NpD test) compares a parametric distribution to a nonparametric distribution,

H0 : X ∼ f (x|θ0 ) vs. H1 : X ∼ fh (x)

Where, θ0 is a scaler or vector belonging to a parameter space, Θ and f (x|θ0 ) is
corresponding probability density function. Also, fh (x) is a kernel density function
with h being the bandwidth.
To visualize this method, we simulated data from two component contaminated distribution 0.8N (0, 1) + 0.2T (4) with different mixing proportions showed in figure
2.1. The original d test computes the L2 distance between the upper two red(one
component fit) and blue(two-components fit) curves, where the two-component fit
is not representing the data well. The NpD test computes the L2 distance between
the bottom two red(Empirical fit) and blue(Nonparametric fit) curves fitted on the
data [60]. The empirical fit emphasized on the 80% data coming from one single component (N(0,1)) which helps in understanding the data better, and the nonparametric
fit represents a smooth fit of the data. Thus, it is evident from our method that the
distance between empirical and kernel fit is more prominent compared to the distance
computed in regular d test. Thus, we get better chance at detecting departures from
homogeneity when data is coming from a contaminated distribution with huge difference in mixing proportion, and do not need to worry about misspecification of the
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hypotheses.

Figure 2.1: Nonparametric d test procedure

The L2 distance puts more emphasis on the larger separations between the homogeneous and heterogeneous density curve. It also leads to a simple closed form expression so that, the test is sensitive to the separation between the null and specific
alternative under consideration. The bigger the distance the more evidence of data
coming from a mixture distribution. For cases where the component mixtures are
equal and the distance between the components are small, we proposed weighted
NpD test in section 2.3. The weight function emphasizes the discrepancies and helps
the L2 distance to detect heterogeneity.

2.2
2.2.1

Nonparametric D test (NpD test)
Definition of non-parametric d test

NpD test measures the L2 distance between fitted Gaussian kernel density and fitted
empirical null density [58]. The empirical null distribution is estimated by obtaining
the center and half-width of the central peak of the standardized data distribution.
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That is, empirical null uses the data to define homogeneity. It protects a user if there
is homogeneity but not the one in expecting (misspecification of the null). Also,
Efron established that, empirical null is better at identifying smaller percentages of
interesting cases compared to theoretical null [58]. Thus we are testing,

H0 : Z ∼ f (z|µ0 , σ02 ) vs. H1 : Z ∼ f (z)

Where Z is the standardized score of the data. µ0 is defined as the center of the z
score distribution and σ0 is defined as the half width of the central peak or curvature
of the center.

µ0 =argmax(f (z));

f(z) is defined as

1
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)
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 d2
σ0 = − 2 log f (z) 2
dz

with, n as the sample size, h as the bandwidth.

The NpD statistic is defined as follows1 :
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In our test, the user can choose their prefered bandwidth. For our further analysis,
we chose an optimal data-based bandwidth by Sheather et.al [61], beacuse of better
theoretical performance and computational advantage [62]. We also explored the
power of the test with some other options of bandwidth selection which is discussed
1

Detailed derivation of the NpD statistic in appendix 5.3.
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in section 2.2.3. All the analyses are preformed in R version 4.1 [63].
2.2.2

Critical Values and relationship with sample size

To understand the asymptotic characteristics of the test, we approached with bootstrap method. We simulated data from N(0,1), N(3,5) and N(7,3)2 distribution.
Sample sizes in between 50 to 1000 were checked for 1%, 5% and 10% levels of significance (α). The critical values for the respective significance levels and sample sizes
were all very similar for all three distribution and fairly linear in logarithmic scale
relationship(Appendix Figure 1). Since obtaining critical values from bootstrap was
time consuming and they were similar regardless of the different means and standarddeviations, we used the average of the critical values with respect to their sample size
and α. Table2.1 shows the fixed critical values obtained from the average bootstrap
simulations to use it for evaluating out NpD test.
Table 2.1: Critical values for nonparametric d test
Sample Size
50
100
200
400
600
800
1000

Level
10%
0.148
0.093
0.058
0.039
0.031
0.027
0.025

of Significance (α)
5%
1%
0.176 0.238
0.112 0.152
0.071 0.097
0.047 0.066
0.038 0.052
0.033 0.045
0.030 0.040

The linear declining trend in Appendix figure 1 shows us the relationship of critical
values and sample size. Theoretically for large number of sample size the null density
and alternative density will be similar and the critical value will go to 0 to keep the
same area under the curve. We further investigated the relationship between sample
size and critical values (Appendix table 1 & figure 2) and found significant linear
relationship depicted in figure 2.2.
2

Standard-deviation
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Figure 2.2: Linear relationship between Log Critical value and Log Sample size

Based on the linear relationship between the log values, linear regression is applied
(Appendix table 2.1) to calculate critical values for any sample sizes based on their
significance level. Table 2.2 shows the necessary coefficients needed to calculate critical values for any sample size.For example, a sample size of n=272, the critical value
at 10% significance level is exp(−0.59702 × log(272) + 0.3639) = 0.051, which is in
between the critical values of n=200 and n=400 from table 2.1.
Table 2.2: Coefficients to obtain Critical values
Significance
Level
10%
5%
1%

Intercept

Slope

0.3639
0.53482
0.844563

-0.59702
-0.59290
-0.592534

The theoretical evidence of the critical values is still under investigations.
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2.2.3

Power of the test:

To analyze the power (probability of not making type-II error), data were generated from normal mixture distributions with different mean and standard deviations
for 10%, 5% and 1% level of significance. Different bandwidth options for example,
‘bw.SJ’, ‘bw.bcv’, ‘bw.ucv’, ‘bw.nrd’, ‘bw.nrd0’ and default ‘0.7’ available in R ‘stats’
package, were explored to see how power fluctuates which is represented in the following figure 2.3 [62, 64–66]. Figure 2.3 shows no severe fluctuations in power when

Figure 2.3: Power curves of 0.5 N(0,1)+ 0.5 N(3,1)for different bandwidths

different bandwidth is used in data simulated from 0.5N(0,1)+ 0.5N(3,1). In fact
they are really close to each other which gives the flexibility to the user to choose
any bandwidth without worrying about fluctuations in results. Thus, the NpD test
is robust to bandwidth selection.
Similar to all other heterogeneity detection tests, NpD test shows increase in power
with the increase in distance among the means of the mixture components. From
figure 2.4, it is evident that the power is higher when the distance among the components mean are 3 and 4 standard deviations respectively, compared to first plot
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where the distance among the components are 2 standard deviation. With different
variance the power did not change much, as we are using z score in our test which
reduces the overall effect of variance.

Figure 2.4: Power curves of different 2-component mixing distributions with different
distance in mean among the component

In regard to using the empirical null which is based on the data, we also investigated
how the mixing proportion affect power in detecting heterogeneity. Figure 3 shows
that, NpD test’s power is higher for mixing proportion in between 0.2 and 0.8, but
not when the mixing proportions are extremely different or extremely similar.
NpD test uses maximum of the density values of z scores as the empirical mean(µ0 =
argmax(f (z))), which largely depends on the skewness of the data. For a 2-component
mixture model, when the mixing proportion is 0.5-0.5, it technically represents a unimodal situation. Similarly when the mixing proportion is 0.1-0.9 there are fewer
values from one component making it harder to detect. When the mixing proportions are different, for example 0.3 and 0.7, the empirical mean will shift toward the
second component with 0.7 mixing proportion and fit a nonparametric curve which
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Figure 2.5: Power curves of 0.5 N(0,1)+ 0.5 N(2,1)for different mixing proportions

will be more skewed compared to a 0.5 mixing proportion (Appendix figure 3).
Thus, the NpD test not only depends on the distance of the means but also the mixing
proportions of the components. To improve the test for extremely similar or drastic
mixing proportions, we proposed a weighted version of the NpD test in section 2.3.
The NpD test was also compared with bootstrap LRT heterogeneity detection method
in different type of mixture or contaminated data. Nonparamteric d test performed
was faster at detecting heterogenetity compared to bootstrap LRT. Power calculation
was attempted but was not completed due to coding issue and time limitation.
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2.3

Weighted nonparametric d test:

2.3.1

Definition and motivation:

Charnigo and Sun [16] used a weight function for normal location/scale case. However
the mean and the standard deviation defined is not similar to our empirical null and
standard deviation. Since we are using z score for our NpD test it is reasonable to
2

µˆ0 )
]. This weight function places more
use the weight function, w(x) = exp[− c(x−
σˆ0 2

weights in the central region around µˆ0 when c > 0.
Based on the chosen weight function and our z score of interest, the weighted NpD
test statistic is defined as3 :
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Similar investigations were run and the critical values were obtained using Bootstrap.
For the nature of the weighted nonparametric test statistic, various weight values were
observed and found to have similar relationship compared to NpD test.
Figure 2.6 depicts the linear relationship between Log Critical value and Log sample
size for regardless of the weight values. Thus, the critical values performs similarly
to unweighted NpD test. Performance for detecting heterogeneity was also compared
and represented in the following figure 2.7.
The above figure 2.7 shows increase in power when the c is higher compared to the
3

Detailed derivation discussed in appendix 5.3
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Figure 2.6: Weighted NpD test Linear relationship between Log Critical value and
Log Sample size

Figure 2.7: Nonparametric d test power comparision with and without weight

unweighted nonparametric d test(c=0). Thus there is a scope to have better power
using higher c values to successfully detect heterogeneity.
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2.4

Proof of Concept:

To understand the application of nonparametric d test on heterogeneity detection we
first used volcanic eruption duration information from faithful data from R [67]. The
duration of eruptions were coded as minutes and contain heterogeneity (Appendix
figure 4). After applying the NpD test the heterogeneity was confirmed and the
results are depicted in table 2.3.
Table 2.3: NpD test result on eruption distribution
Significance
Level
10%
5%
1%

Critical
values
0.051
0.061
0.084

NpD test
Statistic
0.239

Decision
Heterogeneity detected
Heterogeneity detected
Heterogeneity detected

The NpD test was also applied on real data to detect heterogeneity in the discrepancy
among prescribed and practiced fluid removal in the ICU among CRRT (Continuous
Renal Replacement Therapy) patients. The data was obtained from University of
Kentucky clinic from August 2017- April 2021. Initially 1539 adult patients’ electronic
health record were collected. The data derivation is depicted in figure 2.8
The fluid removal data has cumulative fluid removal information on 793 patients
throughout their CRRT duration. There are multiple factors in ICU that disrupts the
fluid removal process and this creates a discrepancy among prescribed and practiced
fluid removal rate. Thus we wanted to see if it is possible to identify subgroup of
patients based on the discrepancy adjusted percentage for CRRT duration (hours)
and weight (Kg) depicted in figure 2.9).
To avoid bias from wrong entry on EHR health record, 1% and 99% exclusions were
applied as there were still some extreme and unrealistic values in the fluid data.
The analysis data have complete information on 777 patients regarding adjusted
discrepancy, whether extra fluid was removed from the body and in hospital mortality.
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Figure 2.8: Fluid Removal Data Derivation Process

Figure 2.9: Distribution of Adjusted Discrepancy % (ml/ Kg h)

Among 777 patient 464 patients died during their hospitalization period. We applied
the NpD test to detect heterogeneity in the adjusted discrepancy among patients.
Table 2.4 shows that there exits heterogeneity in the adjusted discrepancy throughout
CRRT duration but failed to obtain evidence at 1% level of significance. First we
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Table 2.4: NpD test result on Adjusted discrepancy (%ml/Kg h) during CRRT
Significance
Level
10%
5%
1%

Critical
values
0.027
0.033
0.045

NpD test
Statistic
0.041

Decision
Heterogeneity detected
Heterogeneity detected
Not detected

applied bootstrap likelihood ratio test and estimated there may be 3 or 4 components
present in the data. Then using K means clustering, we applied 3 components model
and checked how they behave with mortality adjusting with the under or over fluid
removal information in figure 2.10 [68].

Figure 2.10: 3-Components fit on Adjusted Discrepancy % (ml/ Kg h)

We applied logistic regression to compare the performance of predicting death when
using categorical vs continuous adjusted discrepancy. Table 2.5 shows that, using
grouped adjusted discrepancy obtained from fitting 3 components performs similarly
at predicting hospitalization mortality compared to using numeric values (ROC curve
Appendix 5). With lower AIC (Akaike’s Information Criteria) and higher Sensitivity
value, adjusted discrepancy when analyzed as grouped variable predicts the hospital-
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ization with the additional advantage of risk grouping.
Table 2.5: Model comparison of Grouped vs Numeric Adjusted Discrepancy
Adjusted
discrepancy
%ml/ Kg h
Level
No. of Patients
Actual death
Predicted death
AIC
Specificity
Sensitivity
Optimal predicted
probability cut off
based on accuracy

Categorical

Continuous

1
2
325 317
140 205
0
254
948.78
0.703
0.640

777
464
367
950.43
0.741
0.616

0.452

3
135
119
135

0.681

The results from table 2.5 shows that the adjusting for under or over fluid achievement
the patients in the component 1 are predicted to be healthy or less risk of mortality
(predicted death 0%, actual death 43%), component 3 is at high risk of mortality
(predicted death 100% actual death 88%) and component 2 (predicted death 80%
actual death 65%). Thus using components or categorical version of the information
the clinicians will be able to quickly risk stratify the patients and intervene to adjust
the treatment. Also, this gives an advantage over not worrying about extreme values
when grouped adjusted discrepancy is used.
This is a exploratory investigation to understand how identifying groups will be beneficial compared to just using the continuous information. For future research, we
need to investigate how these groups are related to hospital mortality when adjusted
for other important clinical factors that affects patients health.
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2.5

Discussion:

The nonparametric d test is flexible at detecting heterogeneity compared to other
available parametric heterogeneity detection methods. Although the limitation does
not detect heterogeneity in data with a small distance in mean components and with
an equal mixture, there are still room for improvement using the weighted version of
the test. We propose to further investigate appropriate weight function to adapt to
the unimodal situation.
We showed how identifying components can improve model prediction. This encourages us to apply mixture modeling while adjusting for other covariates’ effects in
improving prediction. In the next chapter, we will identify important risk factors
by doing a systematic literature search on the fluid removal issues in ICU admitted
CRRT patients. After the identifications we will investigate more on the discrepancy
between prescribed and practiced fluid removal rate and how it affects in hospital
mortality.

Copyright© Shaowli Kabir, 2022.

33

Chapter 3 A systematic literature search: Effect of Net Ultrafiltration
(NUF) on Mortality among ICU admitted adults

3.1

Introduction

Over the past decade, one of the frequent complications in the intensive care unit(ICU)
admitted patients or critically ill patients is acute kidney injury (AKI) [28–30]. About
20-50% of ICU patients suffer from AKI and more than half of them are associated
with a greater risk of mortality (50-70%) [69–71]. Overall 5-6% of ICU patients undergo renal replacement therapy or dialysis to reduce mortality [72]. Within a few
hours of ICU admission, the kidney suffers from structural damage and loss of function
which results in complications in administering treatments among ICU admitted patients [73]. As injured kidney cannot filter out enough waste and toxic substances, the
body starts to accumulate excessive fluids, causing fluid overload (FO) [31,40–42,74].
Recent studies have shown that FO>10% of body weight is associated with a higher
risk of mortality and lower renal recovery [44, 75]
To balance body fluid, continuous renal replacement therapy (CRRT) is a popular
treatment, that conducts ultrafiltration 24 hours a day without putting much stress
on the heart [76,77]. Ultrafiltration rate is the suggested volume of fluid removed per
hour according to body weight. Even though ultrafiltration rate is used to reduce FO,
it did not produce sufficient evidence on how to adjust the rate based on patients’
illness severity to mitigate mortality risk [78,79]. A recent proposed net ultrafiltration
(NUF) rate (3.2.3) has become popular to understand the effect on mortality, which is
calculated over the treatment duration, but there are some variability in results [80–
82]. Some studies suggest that less intensive (slower rate or smaller volume) NUF may
be associated with tissue and organ swelling and increased morbidity and mortality
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[46] [47]. Some others suggest a faster rate or larger volume causes hemodynamic and
cardiovascular stress, which also leads to increased morbidity and mortality [48] [49].
Unfortunately, no optimum rate has yet been found.
With inconsistent conclusions among different studies, we systematically examined
the results from randomized controlled trials (RCT) and observational studies conducted on ICU admitted AKI patients undergoing CRRT with the focus on understanding the effect of NUF on mortality and what factors are causing these inconsistencies. If we can identify and control these effective factors, the relationship between
NUF rate and mortality will show a p potential path to obtain an optimum NUF rate
based on the patient’s severity of illness.

3.2
3.2.1

Method
Scope of the Study and Search Strategy

This systematic literature search selected observational and RCT studies that investigated mortality or survival outcomes using NUF among patients who were undergoing CRRT and treated with ultrafiltration. This study was conducted in adherence
with the guidelines of Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) with PubMed, CINHAL and Google Scholar employed as the
primary search databases [83].
There were no restrictions on language, country, or study design, but publication year.
Since the standard definition of FO was proposed in the year 2001, we restricted our
publication search starting from the year 2001 [43]. Key search terms for searching
all databases are presented in Appendix Table 2.
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3.2.2

Eligibility criteria

All studies that investigated the effect of NUF on mortality among ICU admitted
adults undergoing CRRT were eligible for review. To ensure homogeneity, we limited
our study to which followed certain eligibility criteria. Publications excluded in the
study were (1) age ≤ 18 years, (2) review, commentary or editorial article, (3) ESRD
patient, (4) investigated ultrafiltration rate, (5) includes COVID-19 cases, (6) Kidney
transplant patient, and (7) Unavailability of full text or translated text. Based on
the title and abstract, 325 articles were identified, and after removal of duplication
and application of eligibility criteria ,37 articles were assessed for full-text review.

3.2.3

Parameters of interest

NUF is defined as the volume of fluid removed per hour adjusted for patient body
weight over the treatment duration. That is NUF is the treatment performance measurement of CRRT. Due to many other issues impeding the prescribed fluid removal
rate, NUF may account for the gap with the delivered fluid removal rate. The NUF
rate or intensity is measured as follows [44]:

NUF rate (ml/kg/h) =

Total NUF volume (ml)
weight(kg) × treatment duration (h)

Some researchers used days instead of hours based on their research of interest [80].
In many researches NUF has been categorized in three groups (Low: <1.01 ml/kg/h
Moderate: 1.01 to 1.75 ml/kg/h High: >1.75 ml/kg/h) [81, 84, 85]. Apart from
categorized NUF, continuous NUF has also been tested in many researches [80, 82].
The primary objective of this study was to evaluate the effect of different NUF rates on
mortality. We also want to identify how other factors such as sepsis, hypertension, and
illness severity change with NUF. Thus, we compared the clinical characteristics of
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the study patients among these publications. We investigated the statistical analysis
conducted in these studies and performed an appraisal of their appropriateness based
on the presence of indication bias.

3.3
3.3.1

Results
Baseline and clinical characteristics

From 37 full-text assessments, eligibility criteria for study inclusion were applied, and
34 articles were excluded, leaving 3 articles for review. The PRISMA flowchart in
Figure 3.1 portrays the study selection procedure.
The baseline and clinical characteristics of patients studied in the 3 selected literatures
are represented in Table 3.1. Murugan et.al. 2018 [80] was a secondary analysis of
a randomized trial [86] and Murugan et.al. 2019 [81] and Tehranian et.al. 2020 [82]
were observational retrospective. The selected studies took place in Australia, New
Zealand, and the USA. There were a total of 3907 patients with an approximate mean
age of 62 years, and 61.1% of the patients were male. During the studies, 51.2% of
the patients died.
All the selected studies observed mortality at different follow-up times and NUF with
different treatment duration units (Table 3.1). While Murugan et.al. 2018 were interested in one-year survival, Murugan et.al. 2019 and Tehranian et.al. 2020 were
interested in 90 days and 30 days mortality respectively. Tehranian et.al. 2020 also explored 90-day mortality as a secondary outcome. Both Murugan et.al. 2018 and 2019
found nonlinear association of continuous NUF rate with their respective mortality
outcome and selected categorized NUF rate (Murugan et.al. 2018: ≤ 20, 20−25, ≥ 25
ml/kg/day, Murugan et.al. 2019: ≤ 1.01, 1.01 − 1.75, ≥ 1.75 ml/kg/hour) based on
tertiles with lowest Akaike Information Criterion (AIC) value. Tehranian et.al. 2020
selected a categorized NUF rate (≤ 35, ≥ 35 ml/kg/day) based on median value after
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Figure 3.1: PRISMA flowchart of study selection & search strategy

exploring the relationship between continuous NUF and 30-day mortality.
Thus, with different exposure and outcome measurements, we could not apply metaanalysis for quantitative assessment of the studies. But to assess the information, we
dove into the clinical and methodological diversity of the studies for further quality
assessments.
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>1.75
478

1434
Mortality 90 days from
ICU admission
CRRT duration
ml/kg/hour
<1.01
1.01-1.75
479
188 (39)
68.1
(57.2-76.1)
330 (68.9)
100
(83-118)
235 (49.1)
356 (74.3)

477
214 (45)
69.3
(61.0-77.4)
311 (65.2)
101
(84-118)
221 (46.3)
330 (69.2)

Total no. of patient

Exposure measurement
duration and unit
Exposure level
No. of patient in
exposure group
Death (%)
Age
Median (IQR)/
Mean ±SD
Male (%)
APACHE III Score
Median (IQR)/
Mean ±SD
Sepsis (%)
Mechanical
ventilation (%)
371 (77.6)

253 (53.0)

101
(84-117)

283 (59.2)

63.8
(51.4-74.2)

232 (49)

Secondary analysis of RCT

Study design

Outcome

Murugan et.al. 2019
Australia, New Zealand

Study
Country

353 (74.3)

128 (26.9)

95
(70–118)

301 (63.4)

61
(52–69)

331 (70)

475

129 (77.7)

39 (23.5)

91
(71–116)

114 (68.7)

59
(51–71)

100 (60)

166

1075
Mortality 1 year from
ICU admission
CRRT duration
ml/kg/day
≤20
20-25

329 (75.8)

138 (31.8)

91
(69–112)

218 (50.2)

58
(48–70)

258 (59)

434

≥25

Observational retrospective

Murugan et.al. 2018
USA

Table 3.1: Study participant baseline and clinical characteristics

586 (84)

NA

103±29

445 (63.9)

63±15

420 (60)

696

648 (92)

NA

104±30

382 (54.4)

60±15

335 (48)

702

Tehranian et.al. 2020
USA
Observational
retrospective
1398
Mortality 30 days from
ICU admission
CRRT duration
ml/kg/day
<35
≥35

In both Murugan et.al. 2019 and Tehranian et.al. 2020 the median or mean APACHE
III score was higher and the median or mean cohort age was also older compared to
Murugan et.al. 2018. Unlike the other two studies, Tehranian et.al. 2020 did not have
any information regarding sepsis incidence. In Murugan et.al 2019, approximately
50% of patients in each exposure group had sepsis, but Murugan et.al 2018 had a
lower sepsis percentage in each exposure group. Mechanical ventilation was observed
and present in more than half of the study cohort among all three publications.
All of the studies applied some similar exclusion criteria to provide valid comparison
of the results and reduce confounding effects. Murugan et.al. 2019 excluded patients
with missing treatment duration or NUF<0.01 ml/kg/hour. Murugan et.al. 2018
excluded patients with missing baseline weight, NUF, and fluid balance (missing or
<5% of body weight). They also excluded patients if the ICU duration was ≤48
hours and they died within 72 hours of ICU admission. Tehranian et.al. 2020 also
excluded patients with FO<5% of their body weight and patients who died within
24 hours of CRRT initiation.

3.3.2

Methodological diversity

To understand the relationship between NUF and mortality, the studies explored
factors that were significant in both unadjusted and adjusted settings. In table 3.2,
we summarized the potential risk factors and statistical methods applied to investigate
the NUF and mortality relationship.
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Missing
potential
information

Other
adjusted
variables in
the statistical
model

Study
Statistical
method
Adjusted
variables

Murugan et.al. 2019 Murugan et.al. 2018 Tehranian et.al. 2020
Gray’s time-varying
Gray’s time-varying
Logistic regression
survival model
survival model
Age, Sex, APACHE III score, Mechanical ventilation,
ICU to CRRT duration
Race, BMI, Liver
Baseline eGFR, ICU
disease, Admission
& Hospital type,
source, Baseline
BMI, Baseline serum
Region, SOFA score,
eGFR, Sepsis, MAP,
creatinine, Charlson
CRRT duration,
Oliguria, ICU type,
score, Hypotension,
Admission source,
Cumulative vasoprFluid balance.
Region, Cumulative
essor dose, Cumulafluid balance.
tive fluid balance.
Charlson score, Race,
SOFA score,
Sepsis, Diabetes,
Comorbid conditions,
Charlson socre
Vasopressor dose
Hypotension, Diabetes

Table 3.2: Statistical method and adjusted risk factors

Murugan et.al. 2018 and 2019 used Gray’s piecewise time-varying survival model
to evaluate one-year and 90-day mortality respectively. The Gray’s survival model
allows of violation of proportional hazard assumption by using time varying covariates in subdistributional hazard model in the presence of competing risk [87, 88].
Tehranian et.al. 2020 used Logistic regression for 30-day mortality due to assumption violation for Cox’s PH model. In Murugan et.al. 2018, high-intensity NUF (≥25
ml/kg/day) was significantly associated with lower mortality risk until 39 days after
ICU admission compared to low-intensity NUF (≤20 ml/kg/day). When compared
to moderate-intensity NUF (20-25 ml/kg/day) high NUF was associated with lower
mortality until 15 days after ICU admission. In Murugan et.al. 2019, high NUF
(>1.75 ml/kg/h) was significantly associated with higher mortality but only after 6
days of ICU admission. Appendix figure 6 shows the significant results obtained from
these two studies using Gray’s survival model.
To find associated risk factors, all three publications adjusted age, sex, APACHE III
score, mechanical ventilation, cumulative fluid balance, and ICU to CRRT duration
for the association between NUF and mortality. Both Murugan et.al. 2018 and
Tehranian et.al. 2020 adjusted for BMI, fluid balance, or cumulative fluid balance,
and both Murugan et.al. 2018 and 2019 adjusted for baseline eGFR, ICU type,
admission source, and cumulative fluid balance. They have also adjusted some other
variables and missed some potential risk factors to investigate, as shown in table 3.2.
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Not generalizable
Did not check association
with prescribed dose.

Not generalizable.
Did not test interaction.
Did not check if difference
in mortality after hospitalization
is due to any other issues.

Limitations

Measured Confounding bias.
Selection bias.
Indication bias.

Missing information on
potential risk factors.
Did not check association with
prescribed dose.

Measured Confounding bias.
Selection bias.
Indication bias

Propensity score matching.
Analysis of NUF restricted
to 72h or therapy initation.
Analysis of NUF with
different threshold.
Quantitative bias sensitivity
analysis for unmeasured
binary confounder.
Subgroup analysis of patient
with > 20% FO

Unmeasured confounder

Analysis excluding patient
with FO < 5% or died
within 24h of therapy
initiation.
Analysis of NUF with
different category based
on quartiles.
Subgroup analysis for
different ICU types.
Propensity score derived
inverse probability weighting
accounting for early hypotension.

Unmeasured confounder.
Measurement bias

Tehranian et.al. 2020

Murugan et.al. 2018

Unmeasured confounder.
Measurement bias

Murugan et.al. 2019
Propensity score matching.
Analysis of NUF restricted
to 72h of therapy initaiton.
Analysis of NUF with
different threshold.
Analysis of NUF as continuous value.
Analysis of with and without
patient with missing treatment hours.
Stratified analysis of restricting therapy duration
(3 or more days and 5 or
more days)
Subgroup analysis with and
without (organ edema, sepsis,
eGFR>60)
Measured confounding bias.
Selection bias.
Indication bias.

Bias not/
can’t be
addressed

Biases
addressed

Sensitivity
analyses

Study

Table 3.3: Evaluation of bias assessment and sensitivity analysis

To understand the appropriateness of statistical application in the robustness of the
results, we evaluated the assessment of bias and sensitivity analysis. Table 3.3 summarizes the bias assessment among the studies. Since all of them are observational
studies, selection bias and indication bias are inevitable, along with unmeasured confounding bias. For example, the patients are receiving high fluid removal rate based
on their sickness and the high fluid removal may in term cause patients intolerance
and harm other organs and increase the mortality risk. The selected patients are very
sick and thus there already exists a high mortality risk. Also, it is not possible to measure all clinical factors and treatment interruptions. But the studies used appropriate
schemes to reduce the effect of bias in results by doing sensitivity analyses.
The studies still suffer from unmeasured confounding effects due to their observational nature, but regardless of their limitations, all of the studies emphasized the
importance of randomized clinical trials and investigation for optimal NUF rate.
The relationship between NUF and mortality from the studies is not consistent. Table
3.4 shows the conclusions and other findings among the studies. Murugan et.al. 2019
showed that higher NUF (≥1.75 ml/kg/hour) is associated with higher mortality,
which is contradictory compared to the other two studies. Moreover, longer ICU
duration, oliguria, liver disease, and other comorbid conditions are associated with
NUF and mortality.
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Key findings
High NUF(≥1.75 ml/kg/hour)
associated with higher mortality
High NUF(≥25 ml/kg/day)
associated with low mortality
High NUF (≥ 35 ml/kg/day)
associated with low mortality

Study

Murugan et.al.
2019

Murugan et.al.
2018

Tehranian et. al.
2020

Other Findings
High NUF patients had longer
ICU, hospital and mechanical
ventilation duration.
High and moderate NUF patients
had higher prevalence of oliguria
High FO patients benefitted from
high NUF and ICU type and NUF
had significant interaction effect.

Table 3.4: NUF and mortality association among studies

3.4

Discussion

This systematic literature search suggests that NUF is associated with mortality but
cannot identify the nature of the relationship due to conflicting conclusions. More
information and research is needed to characterize the relationship. The cohort of
interest in various studies is different in terms of age, illness severity, exposure measurement, and follow-up time. Even though sensitivity analysis has been performed,
the NUF categories are specific to the individual studies. To reduce inter-study variation and increase agreement in future research, it is helpful to identify a general high,
medium, and low category for the NUF rates.
However, the choice of NUF categories could also be investigated with other related
variables. For example, none of the 37 papers extracted for full-text evaluation explored the relationship of NUF categories with prescribed dose, a limitation acknowledged by, e.g. Murugan et.al. 2018 [80]. Low NUF can be related to low fluid removal
prescriptions, which can be due to the patient’s being less ill compared to patients
who received higher fluid removal prescriptions. Thus, future research should analyze whether the prescribed dose is a potential confounder in the relationship between
NUF and mortality.
Our study is not without limitations. With very little research conducted on NUF
with patients not with ESRD, it is not possible to reach a clear conclusion at this time.
Also, there is a possibility that our study may suffer from positive result bias from
publication (only positive results’ preference for publication), and some studies were
not evaluated due to the unavailability of translated texts. Even though the study
populations are quite different in terms of age and illness severity, we emphasize
multiple inclusion-exclusion criteria to mitigate inter-study variation. Our study
could not identify the actual relationship between NUF and mortality but explored
the advantages and shortcomings of the selected studies. For future research, we want
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to highlight the importance of including clinical information like sepsis, diabetes and
searching for possible interactions between them. Because the effect of the NUF rate
can be different based on different group of patients who may have different clinical
characteristics. Also, the prescription dose might be informative in explaining the
conflicting results.
All the selected studies investigated and confirmed the nonlinear ‘J-shaped’ association between NUF and mortality under the respective follow-up period [80–82]. This
indicates that the effects of NUF can be positive or negative based on a specific
group of patients. Identification of factors causing the nonlinear association would be
imperative in calculating the optimum NUF rate based on patients’ illness severity.
In conclusion, there is a pressing need for a clinical trial to find optimal NUF rates
and understand the nature of the effect of NUF on mortality. With the complications
in implementing clinical trials, more observational studies can also be helpful by
investigating the relationship between prescribed dose and potential interaction effects
to portray the relationship nature of NUF on mortality.

Copyright© Shaowli Kabir, 2022.
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Chapter 4 Assessment of Fluid Removal among CRRT Patients in ICU

4.1

Introduction

Continuous renal replacement therapy (CRRT) is a popular treatment among critically ill patients admitted to the ICU [89–91]. It helps patients in the removal of
excess fluid from their bodies and the maintenance of fluid balance. When the kidneys fail to work effectively, the body stores excess fluid, resulting in fluid overload
(FO). The presence of FO in the ICU raises the risk of adverse outcomes and mortality. [42, 92–94]. During CRRT, patients are given a fluid removal objective (daily
CRRT goal) for each day to maintain bodily fluid balance. While it is ideal to achieve
the prescribed amount of fluid removal, most of the time it is not possible due to the
severity of the disease and other technical challenges in administering treatment. As
a result, there is a difference between the fluid removal rate that is practiced and the
rate that is prescribed.
Theoretically, the less variation in therapy execution, the more fluid equilibrium in
the body, which will assist patients to avoid the adverse effects of FO issues. The
discrepancy could be caused by the patient’s incapacity to tolerate treatment or by
variations in treatment evaluation and management in the ICU [50]. In this study,
we investigated whether the rise in treatment discrepancy is linked to characteristics
that can be measured during CRRT administration in the ICU, and whether they
can be managed or improved to give better healthcare.
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4.2
4.2.1

Methods
Study design and population

Using data from the ICU to 48 hours following the start of CRRT, we investigated
the relationship between fluid removal discrepancy and hospital mortality in CRRT
patients, as well as the characteristics that are associated to changes in the discrepancy. We want to use a prediction model to evaluate the role of disparity in predicting
hospital mortality after 48 hours of CRRT initiation. We ran a longitudinal analysis
using daily fluid data to see how the patient’s sickness and therapy implementation
are linked to the daily change in disparity.
We used electronic health records (EHR) collected from a single-center, retrospective
cohort study of ICU admitted critically ill patients at the University of Kentucky from
August 2014 to April 2021 (from IRB approved study). In the primary analysis of the
hospital mortality prediction, all adult patients who received CRRT and remained
alive for at least 48 hours after the beginning of CRRT were included. Day 0 is the
first day of the CRRT (first 24 hours) determined from midnight, day 1 is the second
24 hours, and so on. To identify the association of daily discrepancy, we focused on a
week’s worth of data on patients who survived at least a week of their CRRT length.
The timeframes and information used for the analysis are depicted in Appendix figure
12 .
Implementation of CRRT does not always begin at day 0 onset for certain patients.
As a result, the intended aim of fluid removal on day 0 is frequently not fulfilled due
to admission at a later time of the day or the suggestion of not enough fluid to be
removed in a short period of time. Since we did not have the whole day’s information
on day 0, we used the CRRT goal from day 1 to correctly identify the discrepancy.
Day 1 fluid information also carries the influence of the treatment at day 0, therefore
omitting day 0 in the analysis will not result in a much loss of information due to the
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information instability.

4.2.2

Data Collection and Management

To adjust for confounding and selection bias and ensure reproducible results, inclusion
and exclusion criteria were applied. Patients with average CRRT goal < 500 ml were
excluded from the study. Also only patients who had both clinical and daily fluid
information available were included in the study. Due to human error there were
patients with incorrect admission date or CRRT start date. Since there is no other
way to know the correct date we had to exclude those patients as well. To understand
the fluid discrepancy effect and ensure we have patients information for at least 48
hours of CRRT initiation all patients who died within 48 hours of onset of CRRT were
excluded from the study. Patients were also excluded if they had received peritoneal
dialysis (PD) or had undergone kidney transplant. Since we could not use day 0
information we included patients based on available information on day 1.
After the application of inclusion-exclusion criteria, 690 patients were selected for the
study. After evaluating extreme observations, to adjust for wrong entry on EHR,
percentile exclusion on patients (< 1% and > 99%) were implemented based on daily
CRRT goal. The choice of percentile exclusion was based on clinical rational and
descriptive analysis. The percentile exclusion for EHR bias resulted in 680 patients,
removing 10 patients from the study (Appendix figure 4.2).
Missing values in the daily fluid data were imputed using successive value imputation
after percentile exclusion. In general, the daily CRRT goal should be prescribed quite
similarly for two days in a row. Thus we imputed missing values on day 0 with day 1
and day 1 with day 2, while missing value 2 was imputed with day 1 and so on. After
manual imputation, on day 1, there were still 8 patients with missing information on
their daily CRRT goal. There were several other variables in the data set that had
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missing values, depicted in appendix figure 7.
The missing values among the clinical and fluid data provided were not more than
25% (Appendix figure 7). To impute other missing values, we relied on multiple
imputation (MI) [95–97]. MI with classification and regression tree is a good solution
since it is robust against outliers, multicollinearity, and also well suited for skewed
data [98, 99]. As there were no missing outcome values and the missing percentage
among the variables was less than 40%, we used MI with CART. To show missing
values are missing completely at random, we applied the ‘mcar test’ in R ‘naniar’
package and obtained a P value of < 0.001. This indicated that the missing values
are not completely at random [100]. That is the data is either missing at random
or non-ignorable. With this limitation we used both the potential variables related
to mortality and other auxiliary variable that may or may not be associated with
mortality to imeplement CART imputation [101].
CART imputation was applied using ‘mice’ package in R [102]. The method generates five (default) sets of data with imputed values and then randomly selects one
value from each imputed set to replace the missing value in the original data. The
distribution comparison of imputed data set and original data is presented in Appendix figure 8 (original data: blue, imputed data: red). The distribution curves for
the majority of missing variables are similar. For some of them the shapes are quite
different but those variables did not have missing values for more than 5%. Thus,
with the limited resources and time constraint, we used CART imputation with the
advantage of random imputation selection.
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4.2.3

Variables of Interest:

Based on clinical perspective, the discrepancy between the prescription and the practiced fluid removal rate measured in percent milliliters is computed as follows:

Discrepancy(%ml) =

Prescribed goal fluid in the body − Net fluid in the body
Prescribed goal fluid in the body
× 100

Since the discrepancy also depends on the treatment duration and body weight, we
selected adjusted discrepancy as the variable of interest to evaluate the discrepancy.
The adjusted discrepancy (%ml/Kgh) is more useful for assessing discrepancy over
weight and treatment hours.

Adjusted daily discrepancy (%ml/Kgh) =

Daily Disrcrepancy
Weight × Treatement hours

The adjusted discrepancy will be interpreted as follows: A negative adjusted discrepancy of 16 ml/Kgh would be defined as the fluid being removed but it was 16%
more than the prescribed goal per kg per hour. A positive adjusted discrepancy of
20 ml/kgh would be defined as enough fluid was not removed and it was 20% less
than the prescribed goal per Kg per hour. There were still some patients with a
high (> ±100%ml/Kgh) daily discrepancy on day 1, as depicted in figure 4.1. We
investigated whether various categorized versions of adjusted discrepancy are better
at identifying patient clusters and predicting hospital mortality.
The primary outcome of interest is hospital mortality after 48 hours of CRRT initiation. We are interested in hospital mortality from day 2 (Appendix figure 12).
Our secondary outcome of interest is daily discrepancy analysis among patients who
survived up to a week from their CRRT initiation. We analyzed patients who had
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Figure 4.1: Adjusted discrepancy at day 1

daily fluid information from day 1 to day 6 (6 days). We explored how actual fluid removed from the machine, other clinical parameters related to sickness of the patients
(end stage renal disease (ESRD), Sequential Organ Failure Assessment (SOFA) Score,
Charlson score, FO%) and demographic information, are related to daily discrepancy
change.

4.3
4.3.1

Statistical Analysis
Primary Analysis

To avoid overfitting the hospital mortality prediction model, 70% of the study patients’ (476 patients) information was selected at random as the train data for building
the model, while the remaining 30% patients (204 patients) information were used to
test prediction performance. Other splitting percentages (40%-60% and 20%-80%)
were also explored, but the initial variable selection did not show much variation.
Some clinical characteristics (e.g. race, ESRD) were similar in more than 80% of the
study patients. Thus, we proceeded with a 30:70 split based on a rule of thumb in
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order to have adequate information on the test data prediction [103, 104].
To check for unadjusted association, Fisher’s exact, Chi-square & t-test (based on the
variable type and distribution) were used. To investigate the categorical version of
the adjusted discrepancy at day 1, manual selection and different statistical clustering
algorithms (K means clustering, EM algorithm from R ‘stat’ and ‘mixtools’ package)
were utilized [64, 105–107]. The K-means and EM algorithm clustering techniques
are sensitive to data with high kurtosis (highly peaked data). Thus, we truncated the
adjusted discrepancy within ± 50% on day 1 to apply these clustering techniques.
Due to the truncation, there were 24 patients omitted from the cluster analysis. These
patients were eventually included in the extreme groups based on their signs of change
(Appendix figure 4.1).
Important variables were investigated utilizing random forest, single regression tree,
logistic regression and gradient boosting for prediction model. R ‘vip’ package was
used to identify first top 10 important variables based on their prediction score for
each methods are shown in appendix figure 9 [108, 109]. Based on the all important
variables identified from various approaches, we fitted a logistic regression (R ‘stat’
package) and conducted stepwise selection to determine the factors that contributed
the most [64]. Other clinically relevant variables (e.g. ICU to CRRT duration,
Charlson Score) were also investigated in the model with the likelihood ratio test
(LRT).
Potential interaction effects were investigated based on the feasible solution algorithm
and prior literature suggestions [44,110]. The feasible solution algorithm was applied
with both with and without fixed main effects. Single regression tree was also used
to identify interaction effects based on their odds of mortality from defined cutoff
points [111]. For initial interaction identification we limited the model to have one
interaction term. After selecting multiple potential interaction effects, we used LRT
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and Akaike information criterion (AIC) values to determine which and how many
interaction term best fits the model.
For final model selection was based on AIC and accuracy from 3-fold cross validation
(CV). We also performed a 10-fold CV but received warnings due to some characteristics separation (race is same among 89% of the patients). To evaluate the fit of
the model and prediction performance, the Hosmer-Lemeshow goodness of fit test,
sensitivity, specificity, and ROC curve were explored among test and train data.

4.3.2

Secondary Analysis

To identify associations with daily discrepancy and clinical factors, a linear mixed
effect model with subject specific random intercept and slope was used. We used SAS
9.4 version for this longitudinal analysis [112]. Initially we explored daily actual fluid
removed, fluid overload at ICU admission, SOFA score at ICU admission and CRRT
initiation, Charlson score at ICU admission, ESRD status, demographic information:
age, race, sex, duration from ICU to CRRT initiation and ICU type.
Several covariance structures: unstructured, topelitz, gaussian errors and exponential
decay were explored. We also explored random group effect based on ESRD, race
and sex. Both quadratic and spline models were compared, and the model selection
was based on AIC, Bayesian information criterion (BIC) and LRT. We used empirical
estimates, as it gives a consistent estimates of covariance structure (robust covariance
estimator) whether or not the fitted covariance structure is true structure.

4.4
4.4.1

Results
Study Population & Clinical Characteristics

There were 680 patients selected to analyze hospital mortality. The cohort derivation
process is represented in detail in figure 4.2.
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Figure 4.2: Cohort Derivation Based on Inclusion-Exclusion Criteria

During hospitalization, patients’ demographic and clinical characteristics from both
test and train data are represented in table 4.1. Because the data came from a
single center research, there isn’t much demographic variation; 90% of the patients
are white. Patients from ‘Asian’ , ‘African/American’ and other races were combined
into ”Non-white” group beacause they were very small in proportion. There were
slightly more male patients than females. No severe differences among the train and
test data were observed. Overall, among 680 patients, 374 (55%) died after 48 hours
of CRRT initiation. That is, more than half of the study patients experience the
event of interest (hospital mortality) according to the descriptive statistics.
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Patient Characteristics
Train Data: N=476
Age
60.5 ( 48 - 68 )
Weight (Kg)
91 ( 77.2 - 108.03 )
Sex (Male)
289 ( 61 %)
Race (White)
426 ( 89 %)
Time from ICU to CRRT Initiation 2.07 (1.12 - 5.63)
Baseline Serum Creatinine (mg/dL) 1.73 ( 1.06 - 3.19 )
Baseline eGFR (ml/min/1.73m2 )
38.11 ( 18.46 - 71.48 )
ICU FO% (L)
2.19 ( 0 - 6.31 )
Charlson Score
5(3-7)
SOFA Score at ICU Start
11 ( 9 - 14 )
SOFA Score at CRRT Start
13 ( 11 - 15 )
CRRT Duration (day)
4.81 ( 2.88 - 8.64 )
Hospital Length of Stay (day)
20 ( 10.67 - 35.85 )
ICU Length of Stay (day)
11.8 ( 6.88 - 22.75 )
ICU Type (Cardio)
153 ( 32 %)
ICU Type (MICU)
267 ( 56 %)
ICU Type (Surgery)
48 ( 10 %)
ESRD
396 ( 83 %)
RRT Dependence
375 ( 79 %)
IABP or VAD
13 (3%)
ECMO
72 (15%)
Mechanical Ventilation
441 (93%)
FO% at CRRT Day 1 (L)
-0.47 ( -1.86 - 1.12 )
Adjusted Discrepancy at Day 1
0.03 ( 0 - 0.08 )
Last SCr
1.58 ( 0.96 - 3.06 )
Last eGFR
43.94 ( 19.17 - 79.36 )
Hospital Mortality
268 ( 56 %)
*Categorical variable: N(%), Continuous variable: Median (IQR)

Test Data: N=204
57 ( 47.75 - 64 )
95.4 ( 78.68 - 113.35 )
123 ( 60 %)
184 ( 90 %)
2.46 ( 1.29 - 4.65 )
1.65 ( 1.02 - 3.27 )
44.28 ( 16.45 - 77.51 )
3.02 ( 0.33 - 9.14 )
5(2-7)
11 ( 9 - 14 )
14 ( 11 - 16 )
4.3 ( 2.65 - 8.48 )
18.95 ( 11 - 38.42 )
11.3 ( 6.47 - 21.4 )
58 ( 28 %)
116 ( 57 %)
27 ( 13 %)
167 ( 82 %)
142 ( 70 %)
3 ( 1 %)
29 ( 14 %)
190 ( 93 %)
-0.39 ( -1.85 - 1.69 )
0.03 ( 0 - 0.09 )
1.43 ( 0.9 - 2.55 )
52.53 ( 23.69 - 84.14 )
106 ( 52 %)

Table 4.1: Patient’s Characteristics Across Train and Test Data Throughout Hospitalization

Patients are admitted to the ICU with a higher median FO% compared to the median FO% at CRRT initiation. This was anticipated as patients receive necessary
treatments to remove excess fluid from the body, thus lowering FO at the beginning
of CRRT. The median duration of CRRT initiation from ICU admission is more than
2 days for both train (2.07 days) and test (2.46 days) data. The median adjusted
discrepancy at day 1 is positive in both train (0.03) and test (0.03) data. That is,
we have more patients in our data who did not meet the prescribed fluid removal
goal than those who attained the goal fluid removal. When comparing the median
SOFA score at both ICU admission and CRRT initiation, there appears to be a slight
increase, which indicates that the patients got more sick and thus had to start CRRT.
In both train and test data, almost 83% have a history of end stage renal disease.
Mechanical ventilation was used by 93 percent of patients during their hospital stay,
but the majority of them started it after 48 hours of starting CRRT.
Among 680 patients, only 289 patients survived for at least a week (up to day 6) from
the onset of CRRT. Thus, the analysis data for the secondary outcome included 289
patients’ daily fluid and demographic information for a week (figure 4.2). We did not
have complete 7-day information for all patients (Appendix table 4). That is, the
data was not balanced. Among 289 patients, 156 (54%) died during hospitalization
after receiving CRRT for at least a week. The median patients was 57 years (IQR:
46-65). There were 62.3% male and 90% of the patients were white.

4.4.2

Unadjusted Association with Primary Outcome

During hospitalization, 56% of patients (268) died in the train data. Based on the
train data, table 4.2 demonstrates an unadjusted relationship between hospital mortality and clinical and demographic factors. We applied t-test and found no evidence
of association between continuous adjusted discrepancy at day 1 and hospital mortality. Similarly, there were no significant relationship with mortality based on baseline
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SCr and eGFR, FO% at ICU admission, Charlson score and SOFA score at ICU
admission (P-value > 0.05).
Table 4.2: Patient’s Characteristics in Train Data by Hospital Mortality
Variable
Alive: N=208
Age
56 ( 47 - 62 )
Weight (Kg)
94.35 ( 80.35 - 110 )
Sex (Male)
121 ( 58 %)
Race (White)
193 ( 93 %)
Baseline Serum
1.68 ( 1.09 - 3.47 )
Creatinine, SCr (mg/dL)
Baseline eGFR
41.41 ( 15.82 - 70.57 )
(ml/min/1.73m2 )
ICU FO% (L)
2.97 ( 0.41 - 7.89 )
Charlson Score
5(2-7)
SOFA Score at
11.5 ( 9 - 13 )
ICU Start
SOFA Score at
13 ( 10 - 15 )
CRRT Start
ICU Type (Cardio)
68 ( 33 %)
ICU Type (MICU)
107 ( 51 %)
ICU Type (Surgery)
29 ( 14 %)
ESRD
164 ( 79 %)
FO% at CRRT
-1.23 ( -2.32 - 0.23 )
Day 1 (L)
Adjusted Discrepancy
0.01 ( -0.01 - 0.05 )
at Day 1
*Categorical variable: N(%), Continuous variable:

Dead: N=268
59 ( 48 - 66 )
96.05 ( 76.25 - 117.15 )
168 ( 63 %)
233 ( 87 %)

P-value
0.06
0.64
0.37
0.06

1.45 ( 0.97 - 3.12 )

0.67

53.99 ( 17.08 - 83.51 )

0.27

3.08 ( 0.16 - 9.68 )
5(3-8)

0.35
0.32

11 ( 9 - 14.75 )

0.74

14 ( 12 - 16 )

0.01

85 ( 32 %)
160 ( 60 %)
19 ( 7 %)
232 ( 87 %)

0.07
0.04

0.42 ( -1.15 - 2.1 )

<0.01

0.05 ( 0.01 - 0.1 )

0.24

Median (IQR)

Even though SOFA score and FO at ICU admission did not show a significant relationship, their values at the beginning of CRRT showed evidence of an unadjusted
association with mortality. Compared to ICU admission, fluid overload declines by
CRRT initiation. The median FO% at CRRT initiation was -1.23. This indicates
less fluid in the body. On the other hand, patients who died during hospitalization,
had a positive (0.42) median FO%, which suggests they had excess fluid in the body.
ESRD status was also associated with mortality and was present in the majority of
the patients who died.
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4.4.3

Adjusted Discrepancy and Hospital Mortality

We decided to examine the adjusted discrepancy as a categorical variable since there
was no indication of a link between continuous adjusted daily discrepancy and mortality. Also based on figure 4.1 it seems reasonable to explore the adjusted discrepancy
as a categorical variable.
Initially, we looked for heterogeneity using data from 656 patients’ adjusting discrepancies on day 1 by applying the nonparametric d test proposed in Chapter 2. The
non parametric d test calculated a test statistic value of 0.26, which is much higher
than the critical values for sample size 600 (5% level of significance: 0.038) and 800
(5% level of significance: 0.033) represented in table 2.1). Thus, we can reject the null
hypothesis and conclude that there exists heterogeneity in the adjusted discrepancy
at day 1. We also applied bootstrap LRT and obtained evidence for the presence of
either 3 or 4 components in the data [13]
At first we used K-means clustering with three components, but the K-means plot
prompted us to utilize four components [105]. We implemented the 4 components
K-means algorithm, which identified 4-clusters among 656 patients (appendix figure
10). We generated and compared 95% and 68.3% confidence interval for the mean
adjusted discrepancy based on each cluster and identified criteria for four groups:
< −8.5%, > −8.5% − 5.5%, > 5.5% − 20% & > 20%.
The EM algorithm was then used to identify another group of clusters using the kmean values as initial values [10]. We identified another 4 groups in the adjusted
discrepancy at day 1, and the distribution of each group is represented in appendix
figure 11. After exploring 95% and 68.3% confidence interval for the mean adjusted
discrepancy based on the identified groups, we developed another criteria to categorize
adjusted discrepancy on day 1: < −6%, > −6% − 3%, > 3% − 40% & > 40%.
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Manual identification of groups (3 groups: < −5%, > −5% − 5%, > 5%; 4 groups:
< −10%, > −10% − 0%, > 0% − 10%, > 10%) was also explored based on the
adjusted discrepancy at day 1 in order to find an association with mortality. After
identifying different categorical versions of the adjusted discrepancy, we investigated
the relationship with hospital mortality. Figure 4.3 depicts the distribution of dead
and alive patients during hospitalization for each selected categorical version of adjusted discrepancy at day 1.

Figure 4.3: Distribution of Dead and Alive Patients for Different Categorical Adjusted
Discrepancy at Day 1

Overall, different levels based on different categorical versions of adjusted discrepancy
have a higher number of dead patients than alive patients. We then applied Chisquare test based on train data to check for an unadjusted association with hospital
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mortality, but no significant results were found for any of the categorical versions
of adjusted disrcrepancy. The unadjusted oddsratio are presented in table ?? which
does not show any evidence (p-value > 0.05; 95% CI includes 1) of association with
mortality. In fact it is noticeable that the 95% CIs are too wide and away from 1
for any version of the adjusted discrepancy variable. This gives us a hint about the
uncertainty of the variable information.
Table 4.3: Unadjusted Odds Ratio and 95% Confidence Interval
Adjusted Discrepancy at Day 1
K means (Ref: >-8.55-5.5%)

EM (Ref: >-6%-3%)
Manual (Ref: >-5%-5%)
Manual (Ref: >-10%-0%)

4.4.4

Level
<-8.5%
>5.5%-20%
>20%
<-6%
>3%-40%
>40%
<-5%
>5%
<-10%
>0%-10%
>10%

OR (95% CI)
1.25 (0.551-2.97)
1.21 (0.797-1.84)
1.18 (0.55-2.62)
1.03 (0.48-2.23)
1.19 (0.81-1.75)
1.2 (0.45-3.45)
0.99 (0.49-2.03)
1.22 (0.83-1.8)
1.11 (0.45-2.84)
0.96 (0.59-1.56)
1.28 (0.70-2.38)

P-value
0.60
0.38
0.67
0.94
0.37
0.71
0.98
0.31
0.82
0.88
0.43

Hospital Mortality Prediction

We used a logistic regression to predict hospital mortality after 48 hours of CRRT
initiation with main effect of adjusted discrepancy at day 1, age, race, SOFA score
at CRRT start, actual fluid removed at day 1, FO% at day 1, ESRD status and an
interaction effect of ICU type and time between ICU admission to CRRT initiation.
Adjusted discrepancy was explored both as a continuous and categorical variable.
All versions of categorical and continuous adjusted discrepancy yielded similar AIC
values (Continuous: 607.21, 3 groups: 608.83, 4 groups:609.03, K-means: 609.02, EM:
609.68)) in the model. Multiple levels of categorical variables contribute to the slight
increase in AIC values, so we can assume that the AICs are not much different among
the models (95% CIs are overlapping). Since we are interested in hospital mortality
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prediction, we performed 3-fold cross validation to compare the accuracy of hospital
mortality prediction presented in figure 4.4. Based on the highest prediction accuracy
and clinical relevance, we selected the categorical adjusted discrepancy based on Kmeans clustering to include in the final model.

Figure 4.4: Prediction Accuracy Comparison: 3-fold CV

The variance inflation factors (VIFs) were calculated to check for multicollinearity,
and none of the main effects had a VIF value more than 3.5. The interaction effect
and related main effect’s VIF value were close to 17, which is safe to disregard for
testing multicollinearity because of its association [113, 114]. Hence, we can say that
the final model showed no effect of multicollinearity and the estimated coefficients
are reliable (appendix table 5).
The final regression model yielded significant evidence of association among mortality
and some important predictors showed in table 4.4. The odds ratio with 95% CI
indicates that actual fluid (L) removed by the machine, FO% (L), age, SOFA score
at CRRT start, having end stage renal disease (ESRD) and interaction effect between
ICU to CRRT duration and MICU showed significant (p-value< 0.05) contribution
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in predicting hospital mortality.
Table 4.4: Multivariate Logistic Regression Model
Variables
Adjusted discrepancy
%ml/Kg h
(Ref: -8.55-5.5%)
Day 1 actual fluid removed (l)
Day 1 FO%(l)
Age
Race (Ref:Non-white)
SOFA at CRRT initiation

Level
<-8.5%
>5.5%-20%
>20%

White
MICU
Surgery
Other

ICU type (Ref: Cardio)
ICU to CRRT duration(day)
ESRD (Ref: No)
ICU start to CRRT duration (Ref: Cardio)

Yes
MICU
Surgery
Other

OR
1.34
0.81
0.44
1.19
1.26
1.03
0.48
1.14
0.77
0.27
2.83
1.00
2.11
1.15
1.07
0.87

(95% CI)
(0.54- 3.46)
(0.43-1.53)
(0.15-1.27)
(1.03-1.39)
(1.09-1.46)
(1.02-1.05)
(0.23-0.96)
(1.07-1.22)
(0.44-1.33)
(0.09-0.74)
(0.13-310.4)
(0.96-1.03)
(1.23-3.63)
(1.05-1.28)
(0.97-1.22)
(0.55-1.18)

P-value
0.54
0.52
0.13
0.02
<0.01
<0.01
0.04
<0.01
0.35
0.01
0.56
0.73
<0.01
<0.01
0.27
0.43

Even with the regression model, adjusted discrepancy at day 1 did not appear to
make a significant contribution in predicting hospital mortality after 48 hours. Table
4.4 shows that the 95% CIs are too wide and still far away from 1. However, the
odds ratio changed for positive discrepancy groups (> 5.5% − 20%: 0.81, > 20%:
0.44). This indicates that, there might be some variable in the model which has
a confounding effect on the adjusted discrepancy. We investigated this by fitting
a linear mixed effect model to the daily adjusted discrepancy using daily fluid and
demographic information.
Table 4.4 demonstrates that patients with ESRD history has 111%(2.11-1) higher
odds of dying during hospitalization compared to patients who do not have ESRD
history holding other information fixed at a certain value. Similarly, with an year
increase in age, the odds of dying during hospitalization increases by 3%. White
patients have lower odds of dying by 52% (1-0.48) compared to non-white patients.

64

With the one point increase of SOFA score at CRRT onset, the odds of dying increases
by 14%. With the increase of 1 L in FO%, the odds of dying increases by 26%. With
1 L change in actual fluid removed odds of dying increases by 19%.
We identified a significant interaction effect between time from ICU admission to
CRRT duration (days) and ICU type MICU (appendix table 5). Among MICU
patients, with one day increase in ICU to CRRT duration the odds of dying is 12.2%
(1-exp(0.14-0.01-0.26)) lower compared to patients who are in Cardio ICU. Similarly
with 1 day increase in ICU admission to CRRT initiation, patients in Surgery have
71.6%(1-exp(0.07-0.01-1.32)) lower odds of dying compared to patients in Cardio. But
the interaction effect failed to prove significant among surgery ICU patients(appendix
table 5). This information indicates patients in the Cardio ICU may be very sick
compared to patients in Surgery or MICU, and are at higher risk of hospital mortality
or implementation of earlier CRRT is more effective among the other ICU types
compared to Cardio.

4.4.5

Prediction Performance on Test Data

After the selection of the final model based on train data, we investigated the prediction performance by applying the model to test data. An optimal predicted probability cutoff of 0.513 was identified based on maximum Youden’s index (function of
sensitivity and specificity) [115, 116]. Using the optimal predicted probability cutoff, we compared the prediction performance in both train and test data for model
validation.
From table 4.5, the model obtained a 68% prediction accuracy on train data and
a 62% accuracy on test data. The sensitivity in the test data was 62% and the
specificity was 63%. Positive predictive value on the test data was 73%. Although
the negative predictive value were somewhat lower in both the test and train data,
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Table 4.5: Prediction Performance Comparison
Metrics
Accuracy (95% CI)
Kappa
Sensitivity
Specificity
Positive Predictive
Value
Negative Predictive
Value

Train Data
0.68 (0.63-0.72)
0.34
0.70
0.65

Test Data
0.62 (0.55-0.69)
0.24
0.62
0.63

0.75

0.73

0.58

0.51

higher positive predictive value indicates a good sign, because we are interested in
correctly predicting hospital mortality to provide more attention to this high-risk
patients. Hosmer-Lemeshow goodness of fit test was performed to check for the
logistic regression fit and did not show any evidence of lack of fit for the train data
(P-value 0.883), but it was marginally significant when the model was fitted on test
data (P-value 0.0501). That means, for test data, the model may not be a good fit,
but we do not have much evidence. This can also arise from the re-estimation of the
odds ratio from the test data.

Figure 4.5: ROC Comparison
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We generated the receiver operating curve (ROC) and area under the curve (AUC)
depicted in figure 4.5 to examine the model further. The AUC values for both train
and test data are slightly higher than 0.7, indicating that the model is capable of
discriminating the categorical outcome variable [117]. That is, both in test and train
data, the model is capable of differentiating between dead and alive prediction to an
acceptable degree.

4.4.6

Secondary Outcome

Daily adjusted discrepancy (%ml/kg h) from day 1 to day 6 were used to fit a linear
mixed effect model. In figure 13, we initially investigated the relationship between
time and adjusted discrepancy by fitting a lowess smooth curve using R package
‘ggplot2’ [118, 119]. Based on the initial investigation, we fitted a linear mixed effect
model with day as quadratic effect. We also compared the initial model with piecewise
linear at day (4) but the quadratic effect model produced lower AIC, BIC and higher
log-likelihood value. Thus, we fitted a linear mixed effect model with both fixed
and random effect for quadratic time effect and random slope and intercept for each
patient to see if the adjusted discrepancy was confounded with any other predictors
obtained in the prediction model and to account for subject-specific variations. We
also explored random effect for the quadratic term in day.
For main effects, we explored ESRD, SOFA score at CRRT, FO%(L) at ICU admission
to account for patients’ sickness, actual removed fluid(L) by machine and time from
ICU to CRRT initiation for treatment effect, and age, sex, race, ICU type to quantify
for demographic information. Model selection was based on AIC, BIC and LRT. We
also checked for interaction over time with actual fluid removed but did not find any
significant evidence. For the final model, we selected the main effects of day, actual
fluid removed, sex, race, esrd and FO% at ICU admission and random group effect
of ESRD. That is different unstructured covariance structure will be fitted based
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on whether the patients have ESRD or not. Table 4.6 shows that only actual fluid
removed from the machine is significantly associated with adjusted fluid discrepancy
over time.
Several covariance stuctures like toeplitz, gaussian error, exponential decay were explored, but based on AIC, BIC and loglikehilood value, unstructred covariance structure with group effect of ESRD produce optimal result within given information.
We also used empirical standard error. Because empirical standard errors are robust
and will produce consistent results even thought the covariance structures are not
correctly identified.
Table 4.6: Daily Adjusted Discrepancy Association
Effect
Intercept
Day
Day2
Actual fluid removed (L)
Sex (Ref: Male)
Race (Ref: Non-White)
ESRD (Ref: No)
FO% at ICU admission (L)

Level

Female
White
Yes

Estimate(95% CI)
15.97 (11.83-20.12)
-0.72 (-1.99-0.55)
0.08 (-0.10-0.26)
-2.58 (-3.02–2.15)
0.52 (-0.69-1.73)
-1.70 (-4.09-0.70)
-0.41 (-2.23-1.40)
-0.03 (-0.09-0.03)

Standard
Error
2.06
0.65
0.10
0.22
0.62
1.22
0.92
0.03

P-value
<0.001
0.26
0.37
<0.001
0.40
0.16
0.65
0.32

Table4.6 shows that, daily discrpancy is significantly related to actual fluid removed
adjusted for FO% at ICU admission, ESRD, race and sex. The estimated coefficents
say that, with 1L increase in actual fluid removed the change in daily adjusted discrepancy over one day increase will be -2.58%ml/kgh, fixing other factors at a certain
value. Even though we did not find evidence of the association of other factors with
adjusted discrepancy, we used this model to understand the effect of treatment implementation adjusting for patients’ sickness. Also, while looking back at the hospital
mortality prediction model results in table 4.4, the odds ratio for adjusted discrepancy
changed for the positive discrepancy group compared to the odds ratio in unadjusted
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association with mortality depicted in table 4.3. Thus, it is safe to conclude that actual fluid removed has a confounding effect on the adjusted discrepancy in association
with hospital mortality.

4.5

Discussion

In this study, we were unable to obtain evidence of a significant contribution of the
discrepancy in treatment towards increased hospital mortality risk among patients
requiring CRRT. The wide 95% confidence interval indicates that the variability in the
discrepancy is very high. We had a lot of patients in both dead and alive group at any
discrepancy level. The exploratory linear mixed effect model was fitted to understand
whether any factor in the mortality prediction model is confounded with the adjusted
discrepancy in predicting mortality. We found that the actual fluid removed from the
machine is significantly associated with the daily discrepancy changes. We did not
have enough patients on the ‘Other’ ICU type, thus the the 95% CI of the odds ratio
represented in table 4.4 is not meaningful.
Our study is not without limitations. Because the data came from observational
research, there might be other confounding factors that weren’t taken into account.
We were not able to use the first 24 hours of CRRT information due to the CRRT goal
not being informative. Future research can overcome this by using an adjusted daily
CRRT goal and calculating the discrepancy accordingly. This study was also a single
center study with very low geographical diversity. Mechanical ventilation, ecmo, vad,
and iabp, which have been relevant in other studies, were not able to be used since for
majority of the patients the period of interest did not overlap. Future research can
focus on the CRRT duration and predict mortality after the completion of CRRT.
Also, because the discrepancy variable is a modified variable of fluid overload, we
couldn’t utilize it in our secondary analysis. We used ICU FO% as a fixed value but
did not find any evidence of association with daily discrepancy change during CRRT.
69

In this study it is evident that using adjusted discrepancy on day 1 is not enough
to predict mortality, and future work should focus on adjusted discrepancy during
the whole period of CRRT to understand how they are associated with mortality.
Along with whole CRRT duration information, it will be more informative to obtain
the clinical factors that caused the discrepancy. This also presses the need for a
multicenter study. We did not have enough geographical diversity in our data. Thus,
we cannot generalize the results to a broader population.
It is evident from this single-center study that we need to use more days of data to
account for all factors influencing their treatment in order to have a clearer picture of
the connection to hospital mortality. We did obtain the importance of fluid overload
in relation to hospital mortality. We have also found that fluid overload is correlated with discrepancy (correlation coefficient: 0.49). It is clear that, more expertise
is needed to understand whether fluid overload and discrepancy should be studied
together or separately.
In the future, we’ll concentrate on data collected throughout the CRRT duration and
how it relates to post-CRRT mortality. We will also explore how daily prescribed
goal is related to daily fluid overload, which might provide a clearer picture of the
treatment’s impact on patients’ hospital mortality risk.
Fluid discrepancy is a novel variable in measuring treatment performance and is
definitely related to fluid removal. The fact that patients in the ICU are frequently
unable to remove fluid as directed is alarming. It may not be solely due to treatment
intolerance. Other factors like the different drug use, other therapies may contribute
also. Thus, more exploration is needed to determine how this disparity relates to
mortality risk in ICU-admitted CRRT patients.

Copyright© Shaowli Kabir, 2022.
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Chapter 5 Final Thoughts & Conclusion

5.1

Heterogeneity Detection & Nonparametric D test

While parametric tests for heterogeneity has been developed based on mixture models,
choice of the null hypothesis has always been a recent issue. The nonparametric D
test overcomes this limitation by using an empirical null distribution based on the
data [58]. Even though the theoretical evidence for the asymptotic properties are still
under construction, by using bootstrap and power calculation, the test has proven to
be successful in detecting heterogeneity in a lot of cases.
Although in some circumstances, the parametric test will have greater power than
the nonparametric test, specially when the null and alternative hypothesis are defined
accurately. But the unique feature of detecting different types of heterogeneity is
sometimes preferable. Also the choice of wrong null hypothesis will lead to wrong
decision making. In large scale hypothesis testing this will increase the type II error.
With the original d-test we risk the possibility of choosing a wrong null hypothesis
but not with non parametric d test [16]. While the nonparametric version has less
power hypothetically, it has a greater probability of avoiding the consequences of a
false null hypothesis.
With the limitation of failing to detect heterogeneity in a small sample size, we
overcome the problem by proposing a weighted version of the test. We have also
provided the option of choosing one’s own bandwidth without worrying about the
change. Other weight functions will be investigated in future studies to test for
power improvement.
We compared our test findings to bootstrap LRT regarding time to detect hetero-
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geneity and power analysis for two component contaminated mixture only and were
pleased with the results. While the bootstrap LRT takes longer to compute than
the nonparametric d-test, it gives an idea of how many components to test. We will
try to include the notion of determining the number of components in data with
heterogeneity as another future path of nonparamteric d test improvement.

5.2

Fluid Assessment among CRRT ICU Patients

Identifying clinical parameters associated with an increased mortality risk has been
a common issue among CRRT patients admitted to the ICU [120–122]. The systematic literature search concluded that more information is needed in regards to
understanding how the prescribed dose is associated with mortality risk. This dissertation provided more knowledge not explored in the previous literature by examining
if treatment implementation discrepancy is also a predictor of increased mortality
risk.
To understand the discrepancy, we limited our analysis to 48 hours of CRRT data in
order to predict hospital mortality after 48 hours. We kept the time window similar
to ongoing AKI research [123–125]. Using only 48 hours of data, our research failed
to find evidence of a link between disparity in therapy application and mortality.
This suggests that we should concentrate our efforts on a broader time frame in order
to fully comprehend the relationship for future research keeping in ming that the
findings might also be affected by the sample size and power of the tests. We also
identified other risk factors that has not been explored before such as, the actual fluid
removed by the machine. Although failing to establish a rationale for prescription
disagreement with an ambitious time-frame window, we uncovered that fluid removal
within 48 hours does contribute in hospital mortality after 48 hours.
Fluid overload has been studied as one of the most important characteristics among
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patients at the risk of mortality undergoing CRRT [44,126]. Our research also showed
similar findings. We also found fluid overload, ICU type age race to have significant
association with mortality as mentioned from the previous literature reviews in chapter 3. The relationship between the prescribed goal and fluid overload should be a
future direction in understanding how they are related to mortality risk using more
than 48 hours of data. We were unable to obtain evidence for some other valuable
pieces of information like mechanical ventilation, use of ECMO, VAD or IABP, because vast majority of patients recorded these information after our study period
of interest. For 28 patients, these information was available after the end of the
CRRT duration. Thus, increasing the timeline window will allow the researchers to
incorporate more relevant information in their mortality prediction.
Due to the severity of their illness, it is desirable to have a prediction model that
will assist ICU patients with CRRT in making necessary modifications in a short
period of time. However, due to the nature of their illness, utilizing a limited time
window forecast is ineffective. Rather, we should focus on discovering major risk
factors that are associated with increased mortality risk and altering the patient’s
treatment accordingly.
While conducting this research, we also faced a time constraint due to data availability, which limited our capacity to explore additional choices to have a better
knowledge of the fluid removal assessment. We did not have data on patients’ critical information regarding sepsis, diabetes, hypertension, and so on. However, with
limited information, we were able to gather several critical findings and future directions that will help us better understand fluid evaluation and contribute to patient
healthcare improvement.
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5.3

Collaborative Approach

In order to gain relevant insights and progress in science, collaborative effort is a
crucial instrument in research [127–129]. Chapters 2, 3, and 4 of this dissertation
rely on the multi-domain knowledge of clinical nephrologists, epidemiologists, and
statisticians. Clinical and epidemiological experts offered domain-specific expertise
about the heterogeneity detection method’s application in Chapter 2. The inclusion
and exclusion criteria for publication selection in Chapter 3 were based on clinical
competence in the field of nephrology and librarian search strategies. Clinical expertise was used to determine disagreement in chapter 4, which was then examined using
epidemiological and statistical insights.
This research would not have been possible without the collaboration of domain experts. In the world of medical science, better healthcare cannot be provided just on
the basis of clinician skill without proof of therapy. A statistician cannot provide
reasoning without first having clinical and epidemiological understanding of the disease. As a result, the researchers can only deliver better and more precise healthcare
solutions if they use a team scientific strategy.
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Appendices

Appendix A: Theoretical details
1. Illustration of nonparametric d-statistic
D test statistic proof:
Z
d=
Z
=



2
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 1 X
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nh i=1 2π
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Let,
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1
;
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m0 = −
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Illustration of nonparametric weighted d statistic
Weighted nonparametric D test statistic proof:
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Appendix B: Tables
Table 1: Modelling Critical values vs Sample size
Model type
Linear model
Linear model
Exponential decay
model

Model
Log cv= a + Log N
Log cv = a+ N

AIC values
-77.43
-44.52

Log (y-θ)=a +bx

3.79

Table 2: Key terms for database search
Population
Acute kidney failure, Acute renal
failure, Acute kidney insufficienc,
Acute renal insufficienc, Acute kidney
injur, Continuous Renal Replacement
Therapy, Hemofi ltration,
Hemodiafi ltration,
Renal Replacement Therapy,
Critical Illness, Critically Ill,
Critical Care, ICU, Intensive
Care Units, Kidney replacement
therapy, Continuous

Exposure

Outcome

Ultra
Fluid
Fluid
Fluid
Fluid

Mortality,
Hospital
Mortality,
Survival rate

filtration, NUF,
Overload, FO,
Management,
Balance,
Removal

Table 3: Adjusted Discrepancy Continuous vs Categorical
Adjusted Discrepancy Comparison
With Continuous Adjusted Discrepancy
With Categorical Adjusted Discrepancy
(over or under)
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AIC
607.21
606.36

LR Test P-value
<0.01

Table 4: No. Patient’s Information Available for Each Day
Day
1
2
3
4
5
6

No. of Patients
277
274
269
262
254
258

Table 5: Logistic Regression Estimates for Hospital Mortality Prediction
Variables
Intercept
Adjusted discrepancy
at day 1
(%ml/kg h)
Actual fluid removed(L)
FO% at day 1 (L)
Age
Race (Ref: Non-white)
SOFA at CRRT start
ESRD status (Red: No)
ICU type (Ref: Cardio )
Time from ICU admission
to CRRT initiation
ICU type \times Time
from ICU admission to
CRRT initiation (Ref: Cardio)

Levels
<-8.5%
>5.5%-20%
>20%

White
Yes
MICU
Other
Surgery

MICU
Other
Surgery

Appendix C: Figures
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Estimate
-3.45
0.29
-0.21
-0.83
0.18
0.23
0.03
-0.73
0.13
0.74
-0.26
1.04
-1.32

Std. Error
0.82
0.47
0.32
0.54
0.08
0.08
0.01
0.36
0.03
0.28
0.28
1.77
0.53

P-value
<0.001
0.54
0.52
0.13
0.02
<0.001
<0.001
0.04
<0.001
0.01
0.35
0.56
0.01

-0.01

0.02

0.73

0.14
-0.14
0.07

0.05
0.18
0.06

<0.001
0.43
0.27

Figure 1: Critical Values Bootstrap vs. Fixed

Figure 2: Model fit on Critical values vs Sample size
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Figure 3: Skewness effect on NpD test

Figure 4: Distribution of eruption duration in minutes
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Figure 5: ROC comparison for Adjusted Discrepancy

Figure 6: Summary of Gray’s survival model result in Murugan et.al. 2018 and 2019
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Figure 7: Missing value percentage

Figure 8: MI performance with CART
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Figure 9: Variable Importance Based on Different Methods

Figure 10: K-means Clusters on Adjusted Discrepancy at Day 1
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Figure 11: Distribution of clusters based on EM algorithm for Adjusted Discrepancy
at Day 1

Figure 12: Timeline and Information of Interest

88

Figure 13: Daily Adjusted Discrepancy Throughout CRRT
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[52] J. Schäfer and K. Strimmer, “An empirical bayes approach to inferring largescale gene association networks,” Bioinformatics, vol. 21, no. 6, pp. 754–764,
2005.
[53] M. Pagel and A. Meade, “A phylogenetic mixture model for detecting patternheterogeneity in gene sequence or character-state data,” Systematic biology,
vol. 53, no. 4, pp. 571–581, 2004.
[54] T. M. Nguyen and Q. J. Wu, “Dirichlet gaussian mixture model: Application
to image segmentation,” Image and Vision Computing, vol. 29, no. 12, pp. 818–
828, 2011.
[55] S. Rattanasiri, D. Bohning, P. Rojanavipart, and S. Athipanyakom, “A mixture
model application in disease mapping of malaria,” Southeast Asian journal of
tropical medicine and public health, vol. 35, pp. 38–47, 2004.
96

[56] J. Detilleux and P. Leroy, “Application of a mixed normal mixture model for
the estimation of mastitis-related parameters,” Journal of dairy science, vol. 83,
no. 10, pp. 2341–2349, 2000.
[57] R. C. Jansen, D. L. Johnson, and J. A. Van Arendonk, “A mixture model
approach to the mapping of quantitative trait loci in complex populations with
an application to multiple cattle families,” Genetics, vol. 148, no. 1, pp. 391–
399, 1998.
[58] B. Efron, “Large-scale simultaneous hypothesis testing: the choice of a null
hypothesis,” Journal of the American Statistical Association, vol. 99, no. 465,
pp. 96–104, 2004.
[59] D. Dacunha-Castelle and E. Gassiat, “Testing the order of a model using locally
conic parametrization: population mixtures and stationary arma processes,”
The Annals of Statistics, vol. 27, no. 4, pp. 1178–1209, 1999.
[60] M. Wand, KernSmooth: Functions for Kernel Smoothing Supporting Wand &
Jones (1995), 2020. R package version 2.23-17.
[61] P. Hall, S. J. Sheather, M. Jones, and J. S. Marron, “On optimal data-based
bandwidth selection in kernel density estimation,” Biometrika, vol. 78, no. 2,
pp. 263–269, 1991.
[62] S. J. Sheather and M. C. Jones, “A reliable data-based bandwidth selection
method for kernel density estimation,” Journal of the Royal Statistical Society:
Series B (Methodological), vol. 53, no. 3, pp. 683–690, 1991.
[63] R Core Team, R: A Language and Environment for Statistical Computing. R
Foundation for Statistical Computing, Vienna, Austria, 2020.

97

[64] R. C. Team, R: A Language and Environment for Statistical Computing. R
Foundation for Statistical Computing, Vienna, Austria, 2013. ISBN 3-90005107-0.
[65] D. W. Scott, Multivariate density estimation: theory, practice, and visualization. John Wiley & Sons, 2015.
[66] S. J. Sheather, “Density estimation,” Statistical science, pp. 588–597, 2004.
[67] W. N. Venables and B. D. Ripley, Modern Applied Statistics with S. New York:
Springer, fourth ed., 2002. ISBN 0-387-95457-0.
[68] J. A. Hartigan and M. A. Wong, “Algorithm as 136: A k-means clustering
algorithm,” Journal of the royal statistical society. series c (applied statistics),
vol. 28, no. 1, pp. 100–108, 1979.
[69] E. A. Hoste, S. M. Bagshaw, R. Bellomo, C. M. Cely, R. Colman, D. N. Cruz,
K. Edipidis, L. G. Forni, C. D. Gomersall, D. Govil, et al., “Epidemiology of
acute kidney injury in critically ill patients: the multinational aki-epi study,”
Intensive care medicine, vol. 41, no. 8, pp. 1411–1423, 2015.
[70] W. Druml, F. Lax, G. Grimm, B. Schneeweiss, K. Lenz, and A. Laggner,
“Acute renal failure in the elderly 1975-1990.,” Clinical nephrology, vol. 41,
no. 6, pp. 342–349, 1994.
[71] P. Susantitaphong, D. N. Cruz, J. Cerda, M. Abulfaraj, F. Alqahtani,
I. Koulouridis, and B. L. Jaber, “World incidence of aki: a meta-analysis,”
Clinical Journal of the American Society of Nephrology, vol. 8, no. 9, pp. 1482–
1493, 2013.
[72] M. Heung, S. M. Bagshaw, A. A. House, L. A. Juncos, R. Piazza, and S. L.
Goldstein, “Crrtnet: a prospective, multi-national, observational study of con-

98

tinuous renal replacement therapy practices,” BMC nephrology, vol. 18, no. 1,
pp. 1–7, 2017.
[73] K. Makris and L. Spanou, “Acute kidney injury: definition, pathophysiology
and clinical phenotypes,” The clinical biochemist reviews, vol. 37, no. 2, p. 85,
2016.
[74] J. Bouchard, S. B. Soroko, G. M. Chertow, J. Himmelfarb, T. A. Ikizler, E. P.
Paganini, and R. L. Mehta, “Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury,” Kidney international, vol. 76, no. 4, pp. 422–427, 2009.
[75] A. S. Messmer, C. Zingg, M. Müller, J. L. Gerber, J. C. Schefold, and C. A.
Pfortmueller, “Fluid overload and mortality in adult critical care patients—a
systematic review and meta-analysis of observational studies,” Critical care
medicine, vol. 48, no. 12, pp. 1862–1870, 2020.
[76] A. Tolwani, “Continuous renal-replacement therapy for acute kidney injury,”
New England Journal of Medicine, vol. 367, no. 26, pp. 2505–2514, 2012.
[77] S. Tandukar and P. M. Palevsky, “Continuous renal replacement therapy: who,
when, why, and how,” Chest, vol. 155, no. 3, pp. 626–638, 2019.
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